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ABSTRACT
Phosphorylation is a post-translational modification important for regulating
protein activity and protein binding capacity. It is used in many different signaling
pathways within the cell. Src Family Kinases and Protein Kinase A (PKA) are two
prototyptical non-receptor tyrosine and serine/ threonine kinases, respectively, which are
found in canonical signaling pathways. These two kinases are critical for signaling in
essentially every cell of a multicellular organism, and are particularly important in
development, cell migration and proliferation. Although both proteins have been
intensely studied for many decades, an understanding of the molecular mechanisms
which govern their regulation and the regulation that they effect on other proteins are still
being elucidated.
Fyn, like its related Src Family Kinase members, has previously been shown to be
regulated by two tyrosine phosphorylation events at residues Y420 and Y531. Y420 is
located in the kinase (Src Homology 1(SH1)) domain and it is a highly-characterized
intermolecular autophosphorylation site that increases the activity of the kinase. Y531 is
located near the C-terminus and is phosphorylated by C-terminal Src kinase (Csk).
Phosphorylation of Y531 allows it to bind to R176 in the SH2 domain in an
intramolecular fashion. In this conformation Fyn has only basal activity. Since these
sites are essential for regulating the activity of the kinase, we hypothesized that four
novel sites of tyrosine phosphorylation in Fyn could also importantly regulate the protein.
Three of the novel sites lie in the SH2 domain, and one is located in the kinase domain.
Mass spectrometry, in vitro kinase assays, as well as western blot analysis aided in
uncovering that these novel Fyn phosphorylation sites fine tune the activity and substrate
binding of the protein.
PKA has been implicated in a multitude of signaling pathways and is particularly
important in cell growth, proliferation, and migration. Fyn and PKA have classically
been considered to be in separate signaling pathways. However, research over the past
several decades has provided evidence that there is crosstalk that exists between the two
pathways. The SFK Fyn and PKA can phosphorylate each other, thereby regulating each
other’s activity. Based on these data, we hypothesized the existence of downstream
effectors of this relatively uncharacterized pathway. It was hypothesized that the
presence of Fyn could lead to PKA activation and to differences in PKA binding partners.
Through the use of co-immunoprecipitations, Stable Isotope Labeling of Amino Acids in
Cell Culture (SILAC) and quantitative mass spectrometry, many proteins were found to
increase their binding to PKA in the presence of Fyn. Several proteins were selected and
further biochemically validated. These data suggest that the presence of Fyn could allow
for PKA to more importantly interact with discrete pools of proteins within the cell to
effectuate its signal transduction. Together these studies provide understanding on
critical and fundamental processes by which all cells function.
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This dissertation describes regulation of Src Family kinases through novel
tyrosine phosphorylation events (Chapter 2). In order to better understand these
mechanisms of regulation, a literature review describing what has been learned over the
past century with a focus on how tyrosine phosphorylation has previously been shown
to regulate SFK activity is described in Chapter 1. Furthermore, at the end of Chapter 1
there is also a section describing studies of crosstalk between SFKs and PKA. This
topic will be focused on in more detail in Chapter 3.
CHAPTER 1: SFKs and RTK signaling: from past to present
1.1. Overview/critical history
Historical significance: Src is a kinase that phosphorylates tyrosine
The history of Src spans back to the early 1900’s when the virus encoding it was
first described by Peyton Rous. This medical pathologist found what he described to be
sarcomas in chickens that were able to metastasize when cell-free filtrates were injected
into the breast of an uninfected animal (Rous, 1911). Tumors from the Plymouth Rock
chicken were ground up with sand, centrifuged, and filtered to remove all the cells
including lymphocytes and red blood cells. Cells of a spindle-shaped histology were
found in the subcutaneous tissue. Rous’ paper in 1911 consists of extensive depictions of
tumor cells from injected chickens. Pathology differences were readily apparent between
chickens that were injected with ground-up tumor versus those that were injected with
cell-free filtrates. Chickens injected with ground-up tumor developed nodules as soon as
one week later. Those injected with cell-free filtrates still developed tumors but at a
reduced rate in comparison, anywhere after ten days to three weeks. At the end of his
1

manuscript, Rous described the transmission of tumors to be independent of cells. How a
cell-free filtrate was able to produce sarcomas seemed perplexing in the early 1900’s, and
resulted in a certain degree of skepticism. However, as the century progressed, others
found that viral agents are able to produce tumors in hosts (Martin, 2001). Dr. Rous
received the Nobel Prize in Physiology or Medicine in 1966 for this pioneering work
which lead to the identity of tumor-causing viruses.
In the 1970’s, v-src was identified through a series of genetic studies as the viral
gene responsible for tumorigenesis (Martin, 1970). Kinase activity of the protein that
coded for v-src was found later in the 1970’s. Phosphate from radiolabeled [γ-32P]ATP
was transferred to the heavy chain of rabbit IgG during in vitro kinase reactions
performed on anti-src immune complexes from cells that contained the v-Src protein,
which at the time was called Src phosphoprotein of 60 kDa or pp60src. No
phosphotransfer was observed when immune complexes were derived from extracts that
did not contain pp60src. The antibodies to v-Src were produced in rabbits carrying v-Srcinduced tumors. Together these results suggested that v-Src had phosphotransferase
activity and that a hyperactive kinase might be responsible for v-Src-induced tumors
(Erikson et al., 1979). The following year, Hunter and Sefton found that v-Src was able
to specifically phosphorylate tyrosine residues. Phospho-amino acid analysis was
performed on similar immune complex assays as those conducted earlier (Erikson et al.,
1979) and markers for phosphoserine, phosphothreonine, and phosphotyrosine were
added to the thin layer chromatography analyses. The 32P from the IgG heavy chain
tracked with phosphotyrosine. In additional analyses they found that v-Src itself was
2

tyrosine phosphorylated when purified from infected cells (Hunter and Sefton, 1980).
Interestingly, chicken cells which were infected with v-Src had significantly higher levels
of phosphotyrosine compared to uninfected cells, suggesting an increase in kinase
activity (Hunter and Sefton, 1980).
Uncovering differences between v-src and c-src
Elucidation of v-src and c-src properties has developed over the past twentieth
century. While v-Src was shown to transform cells, this was not observed in its cellular
counterpart (Iba et al., 1984). However, when the C-terminus of c-Src was mutated, the
protein gained the ability to transform cells (Iba et al., 1984). Takeya and Hanafusa
determined the coding sequences of v-src and the cellular homolog c-src. Alignment
showed almost complete sequence identity, except for a C-terminal truncation in v-Src.
Specifically, the last 19 amino acids in the C-terminus of c-src were found to be replaced
by 12 different amino acids in v-src (Takeya and Hanafusa, 1983). The C-terminus was
further analyzed, and the changed nucleotide sequence coding of these amino acids was
found 900 base pairs (bp) past the termination codon in c-src. These data suggest a
recombination event of v-src, and that this is occurring at the DNA level, looping out of
approximately 900 base pairs.
C-terminal phosphorylation negatively regulates c-Src kinase activity
A phosphorylation site was found at Y527 of pp60c-src, which is absent in the viral
counterpart (Cooper et al., 1986). Tryptic and chymotryptic peptides were mapped by
two-dimensional separation, whereby tyrosine phosphorylation sites in discrete tryptic
peptides were identified. Based on the sequence of amino acids in the C-terminus, the
3

two possibilities of phosphorylation were Y519 and Y527. Chymotrypsin does not
cleave after phosphorylated tyrosines, which would result in a different sized peptide if
Y519 were phosphorylated. Based on these properties pY527 was first inferred (Cooper
et al., 1986), and many biochemical studies have been performed since which validated
the discovery of pY527, and which have revealed how this site regulates c-Src.
Phosphatase treatment and phosphopeptide mapping was also shown to remove
phosphorylation on Y527 of pp60c-src (Cooper and King, 1986). This phosphatase
treatment was also shown to increase the protein’s kinase activity towards enolase
(derived from rabbit muscle) as a substrate in an in vitro kinase assay (Cooper and King,
1986). Additionally, the use of an antibody which recognizes a small portion of the Cterminus of pp60c-src from injected rabbits prevented Y527 phosphorylation (Cooper and
King, 1986). Furthermore, when c-src Y527 was mutated to a phenylalanine to prevent
phosphorylation from occurring, the activity and oncogenic properties of the kinase
increased (Piwnica-Worms et al., 1987).
Upon identification of Y527 phosphorylation in Src, a question arose as to
whether this site was an autophosphorylation site, or whether another kinase
phosphorylates that particular residue. Cooper and King suggested that since only low
amounts of autophosphorylation activity were detected on Y527, another kinase might be
primarily responsible for phosphorylating that particular residue (Cooper and King,
1986). C-terminal Src kinase (Csk) was identified by co-purification with pp60c-src in
neonatal rat brain. When a kinase assay was performed with pp60c-src and N-PTK, an
increase in phosphorylation of pp60c-src was observed (Okada and Nakagawa, 1988).
4

Autophosphorylation of Src Y416
Phosphorylation sites on Src were characterized with metabolic labeling and in
vitro phosphotransfer assays (Smart et al., 1981). Reactions were run on polyacrylamide
gels, digested with trypsin, and subjected to reverse-phase chromatography to fractionate
samples. Under these methods, a certain phosphopeptides were identified in eluted
fractions and they were further analyzed by Edman degradation. A phosphotyrosine was
found at the Src Homology 1 domain of v-Src and c-Src when antisera from tumorbearing rabbits was used to immunoprecipitate metabolically labeled chicken embryonic
fibroblasts. A second site was also identified on both and determined to be tyrosine 419
in human c-Src (Smart et al., 1981). In vitro kinase assays of immunoprecipitated v-Src
also showed it to be phosphorylated, suggesting autophosphorylation. Human Y419 in cSrc is analogous to chicken c-Src Y416. When Y416 was mutated to a phenylalanine and
the mutant was immunoprecipitated and subjected to in vitro kinase assays toward
enolase, the Y416F mutant showed a decrease in enolase phosphorylation (PiwnicaWorms et al., 1987). Surprisingly, a dramatic increase in enolase phosphorylation was
observed in the Y416F/Y527F mutant. Mutants were also stably expressed in mouse
NIH 3T3 cells, immunoprecipated with an α-phosphotyrosine antibody, and western
blotted with α-phosphotyrosine. The highest level of tyrosine phosphorylation was seen
the Y527F mutant (Piwnica-Worms et al., 1987). These data suggest that low kinase
activity in the Y416 mutant can be overcome through the inability of Y527 to be
phosphorylated.
As the function of Src Y416 began to be uncovered, another question that arose
5

was whether the site was autophosphorylated, or phosphorylated by another kinase in the
cell. One way to study autophosphorylation is through expression in a system that does
not contain endogenous kinases. Yeast do not contain tyrosine-specific kinases, and were
used by Cooper and MacAuley to determine whether Y416 (and also Y527) sites in Src
were autophosphorylated. Several mutants were created to analyze this question: one
mutant that was able to accept but not donate a phosphate (i.e., kinase dead), and one
mutant that contained catalytic activity but couldn’t be tyrosine phosphorylated at certain
residues (i.e., phenylalanine mutants). These mutants were expressed in yeast to
determine whether phosphorylation at specific tyrosine sites were the results of
autophosphorylation. Phosphorylation of p60F527 and p60WT were similar, but there was a
great reduction of tyrosine phosphorylation in p60F416 and p60F416/F527 mutants (Cooper
and MacAuley, 1988). Interestingly, however, there remained some tyrosine
phosphorylation in the pp60F416/F527 mutant. Furthermore, phosphorylation was also
determined to be intermolecular as it was evident in cells that expressed both p60R295
(kinase dead mutant) and p60F416/FY527, as well as when single mutants were expressed
and lysates mixed together., or when expressed separately and their immune complexes
were mixed in in vitro kinase assays. The kinase dead, on the other hand, showed no
tyrosine phosphorylation when expressed on its own or in in vitro kinase assays on its
own. These studies were able to determine that Y416, as well as Y527 are sites of
autophosphorylation, and that Y416 is the primary site of intermolecular
autophosphorylation, while Y527 can also be phosphorylated by Csk (Cooper and
MacAuley, 1988).
6

The kinome: SFK evolution
In 2002, with the human genome close to being finished, a better idea of the
“kinome” began to unfold. 518 kinase genes were identified by Manning and others
using genomic data. Of all the genes in the human genome, kinases comprise around
1.7% (Manning et al., 2002). Most of these proteins are part of a superfamily that
possess a catalytic domain. Several groups of kinases were identified including the
tyrosine kinase superfamily. These proteins are divided into two types: receptor tyrosine
kinases and non-receptor tyrosine kinases (Cetkovic et al., 2004). There are 30 families
of tyrosine kinases, with 90 members found in humans. Tyrosine kinases are found in
human, worm, and fly, highlighting that they expanded and importantly evolved at the
beginning of the Metazoan era (Manning et al., 2002). Tyrosine-specific kinases are not
found in yeast, other fungi, or plants, indicating a restriction of most protein tyrosine
kinases to Metazoa. However, there are some single-celled eukaryotes that do contain a
few tryrosine-specific kinases, including SFKs.
There are currently 11 family members of the SFK family in vertebrates,
including Src, Yes, Fyn, Fgr, Lck, Hck, Blk, Lyn, Frk, Brk, and Srm. There were
initially two subfamily classifications: SrcA and SrcB proteins. The genes that encode
these proteins formed through ancestral gene duplication (Cetkovic et al., 2004). SrcA
includes Src, Yes, Fyn and Fgr, while SrcB includes Lck, Hck, Blk, and Lyn (Hughes,
1996). The evolution of Src dates all the way back to unicellular organisms. Orthologs
of Src have been investigated in the unicellular organism Monosiga ovata, as well as the
multicellular sponge Ephydatia fluviatilis (Segawa et al., 2006). Choanoflagellates are
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unicellular organisms that are the closest relative to Metazoans. These organisms express
Src with 50-60% amino acid sequence identity to the human form. The C-terminal
tyrosine is also conserved in M. ovata, but the surrounding amino acids are not. Negative
regulation driven by phosphorylation of the C-terminus is specific to Src family kinases;
no other kinases are regulated in this manner. However, negative regulation driven by
Csk phosphorylation does not seem to be apparent in M. ovata when investigated with
biochemical techniques (Segawa et al., 2006). This suggests that there has been an
evolution in function when moving from unicellular to multicellular organisms.
Suberities domuncula, a marine sponge classified in the phylum Porifera, was found to
have five genes that code for three proteins related to Src: SRC1SD, SRC2SD, and
SRC3SD. Their proteins were also found to have the closest homology to Src and Yes in
vertebrates. Phylogenetic analysis of this organism concludes that sponge Src genes are
ancestral to vertebrate Src genes.
The SH2 domain: conservation and function
Src Homology 2 (SH2) domains are non-catalytic regions important for
coordinating protein-protein interactions in the cell through binding to phosphotyrosine
residues on other proteins (Koch et al., 1991). There are 120 proteins that contain SH2
domains in humans, including 30 tyrosine kinases and 90 non-kinases. Those that do not
contain catalytic domains can act as adaptor proteins. One example of important SH2
domain interactions is found in growth factor signaling through tyrosine kinase receptors.
A growth factor binding to its respective tyrosine kinase receptor allows for receptor
dimerization and intermolecular autophosphorylation of the receptors (Koch et al., 1991).
8

Phosphorylation allows for SH2-containing proteins to bind to phosphotyrosines on
receptor tyrosine kinases (RTKs), allowing for cytoplasmic signaling (Hidaka et al.,
1991). Sequence alignment of SH2 domains show clear conserved hydrophobic regions
(Russell et al., 1992). The FLVRES residues in Src have been shown to be important for
phosphotyrosine binding. For Src, this includes binding not only to phosphotyrosines on
other proteins, but to pY527 on itself. Dephosphorylation of Src Y527 allows for the
SH2 domain to better interact with other proteins (Koch et al., 1991). However,
Songyang et al. showed that the SH2 domain of Src preferred to bind certain other pY
motifs better than to pY527 (Songyang et al., 1993). Arginine residues are also
conserved in almost all SH2 domains, and serve as a necessary positively charged residue
for the phosphate to bind (Russell et al., 1992). There is a high degree of conservation of
the eight amino acids G(S/T)FLVR(E/D)S in many proteins which possess SH2 domains.
In order to test whether this sequence is important for binding, peptides of this sequence
were synthesized and an in vitro binding competition assay was performed.
Phosphorylated EGFR is normally able to bind to the SH2/SH3 domain of
phosphoplipase C (PLC) contained on sepharose beads. This competition assay revealed
that GSFLVRES peptide prevented binding of the EGFR to the SH2 domain of PLC
(Hidaka et al., 1991). Conservation of this sequence suggests its importance in
recognition of phosphotyrosines in SH2 domains.
The SH3 domain: another mode of protein-protein interactions
Src Homology 3 domains are found in a variety of both kinase and non-kinase
proteins. The domain is around 60 amino acids and in many cases is found linked to an
9

SH2 domain (Ren et al., 1993). Nuclear magnetic resonance and crystal structure were
originally used to determine the structure of Src’s SH3 domain (Yu et al., 1992). The
structure consists of two β sheets, and the binding site is hydrophobic with aromatic side
chains. The residues necessary to bind to SH3 domains were originally identified with
the protein 3BP1 and its interaction with the tyrosine kinase Abl’s SH3 domain. This
was accomplished by mutating specific residues to alanine and monitoring differential
binding (Ren et al., 1993). It was found that mutations of specific prolines to alanine
residues abolished the binding of 3BP1 to the SH3 domain of Abl. Because it seemed as
though these proline residues were necessary for binding, a peptide of 10 prolines was
used to determine if it would bind to the SH3 domain. This however did not occur,
suggesting that other amino acids were also necessary for the binding. Sequence analysis
of other proteins which bind to SH3 domains was performed, and it was determined that
binding regions had characteristics of hyrodphobicity and were proline rich, and
generally fell in a PxxP motif (Ren et al., 1993).
Growth factor signaling and their regulation of SFK activity
The classic receptor tyrosine kinase pathway is characterized by the binding of a
particular growth factor to its receptor. This leads to a conformational change resulting
in trans-autophosphorylation at tyrosine residues, as well as dimerization of the receptor
(Ciardiello and Tortora, 1998). Phosphorylation of the receptor can allow for the binding
of adaptor proteins and propagation of the MAPK signaling pathway, among others. The
Src family kinases are able to bind to activated growth factor receptor phosphotyrosine
residues through their SH2 domains, increasing intermolecular autophosphorylation at the
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equivalent of Src Y416 and thereby allow subsequent kinase activation (Bromann et al.,
2004). Phosphorylation of SFKs can also be accomplished by the RTKs themselves; Src,
Fyn, and Yes are known to be phosphorylated by the Platelet-Derived Growth Factor
Receptor (PDGFR) (Koch et al., 1991). Work by Tony Hunter and others began to
uncover a relationship between particular growth factors and Src’s activity. Here I
specifically focus on the relationship that has been observed between Platelet-derived
growth factor (PDGF), PDGFR, and Src. Stimulation of fibroblast cells with PDGF
increased Src’s activity, as evaluated in an immune complex kinase assay using enolase
as a substrate (Gould and Hunter, 1988). PDGF stimulation also caused N-terminal
phosphorylation of Src. Approximate locations were identified by peptide mapping and
the use of S. aureus V8 protease. Gould and Hunter proposed that the site of tyrosine
phosphorylation could be Y90 or Y92.
Later work also found that activation of PDGFRs resulted in the phosphorylation
Src at a site other than Y416 and Y527. Peptide sequencing and tandem mass
spectrometry identified pY213 (Stover et al., 1996). Furthermore, phosphorylation of Src
Y213 prevented binding to Src’s C-terminal sequence and increased kinase activity.
Analysis of crystal structures indicated that the phosphopeptide which binds to the SH2
domain was very close to Y213, suggesting that the interaction of the positively charged
R205 residue with the glutamic acid on the phosphopeptide could be disrupted when
Y213 was phosphorylated (Stover et al., 1996). This observation will be important for
data shown in Chapter 2 of this dissertation.
Growth factor signaling and Protein Kinase A
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PKA is a holoenzyme consisting of two catalytic subunits bound to two regulatory
subunits. PKA activity increases when cAMP levels are elevated within the cell. cAMP
allows for dissociation of the holoenzyme by binding to the regulatory subunits, leaving
the catalytic subunits free and active (Wong and Scott, 2004). cAMP is produced by a
class of enzymes known as adenylyl cyclases, which convert ATP to cAMP, while
phosphodiesterases are responsible for degrading cAMP (Conti and Beavo, 2007).
PDE4, 7 and 8 solely hydrolyze cAMP, while PDE 1, 2, 3, 10 and 11 are able to
hydrolyze both cAMP and cGMP to AMP and GMP respectively. Over 20 proteins have
been found that correspond to four PDE4 genes, and differences in variants of a particular
PDE allow for very specific subcellular localization (Conti and Beavo, 2007). PKA has
been shown to phosphorylate class 4 phosphodiesterases, which leads to activation of the
enzyme (Sette and Conti, 1996). This event provides a means for the kinase to negatively
regulate its own activity through phosphodiesterase-dependent control of cAMP levels.
Due to the wide variety of cellular processes in which PKA is involved in, mechanisms
have evolved for the kinase to be localized to specific areas of the cell at certain times.
A-kinase anchoring proteins (AKAPs) aid in localizing PKA to these very specific
subcellular domains to allow for appropriate signaling. A wide variety of AKAPs have
been identified, and have been shown to bind to both type I (i.e: RIα, RIβ) and type II
(i.e: RIIα, RIIβ) regulatory subunits (Wong and Scott, 2004).
Activation of PKA was originally identified to occur downstream of G-proteincoupled receptors (GPCRs). Following activation of a GPCR, adenylyl cyclase is
activated resulting in increases in the second messenger cAMP. cAMP then binds to the
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regulatory subunits of cyclic AMP dependent protein kinase A (PKA). In more recent
decades however, increasing evidence has demonstrated that PKA can also be activated
downstream of growth factor signaling pathways. The full mechanisms are not
completely understood, and it seems as though PKA’s involvement can be somewhat
complex. There have been several studies that have implicated PKA in regulating the
MAPK/ERK pathway downstream of growth factors (Bornfeldt and Krebs, 1999). As
mentioned previously, ligand binding to growth factor receptors allows for transautophosphorylation at tyrosine residues, which can allow the binding of proteins
containing phosphotyrosine binding domains (like SH2 and PTB domains). One example
is the adaptor molecule Grb2 which contains one SH2 and two SH3 domains. Upon
activation and phosphorylation of the EGFR, Grb2 binds to the receptor through its SH2
domain (Ciardiello and Tortora, 1998). Proline-rich regions of SOS (Son-of-Sevenless)
are able to bind to the N-terminal SH3 domain of Grb2 upon EGF stimulation, as
discovered through mutational GST pulldowns (Rozakis-Adcock et al., 1993). SOS is a
guanine nucleotide exchange factor which facilitates GTP loading in Ras (Fishman et al.,
1997). Ras-GTP can recruit Raf dimers to the membrane where they autoactivate and
initiate the MAPK signaling cascade through serine/threonine phosphorylation. This
signaling cascade eventually modulates transcription factors to regulate cell growth and
proliferation, among other processes. Therefore, upon RTK activation Grb2 is able to aid
in the propagation of the MAPK signaling cascade through interactions with its own SH2
and SH3 domains. In early papers it was suggested that the RIα subunit of PKA could
potentially bind to SH3 domains of Grb2 through a stretch of amino acids (84-92)
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containing prolines and uncharged residues (Skalhegg et al., 1994). Subsequent studies
have shown that indeed PKA is able to bind directly to Grb2’s SH3 domain (Tortora et
al., 1997). This binding event could have the potential to alter MAPK signaling in a
PKA-dependent fashion.
PKA also seems to be involved in the RTK signaling pathway upstream of Grb2
at the receptor level of the pathway. Interaction between PKA and the EGFR occurs only
with PKAI, and not PKAII (Tortora et al., 1997). Co-immunoprecipitations between the
EGFR and PKA RIα revealed the binding of the two proteins, which was highest five
minutes after EGF stimulation. Furthermore, PKAI is active when bound to the EGFR as
shown when anti-EGFR immune complexes were blotted for PKACα . On the other
hand, RIIβ does not seem to interact with the EGFR. Grb2 and RIα bind to one another
independent of growth factor stimulation, specifically at the N and C-terminal SH3
domains of Grb2. RIα was not able to bind to the SH2 domain of Grb2 (Tortora et al.,
1997). These data suggest that there may be isoform specificity of PKA regulatory
subunits and components of the RTK signaling pathway.
Growth factor signaling is important for release of specific proteins from cell
membranes to allow for initiation of signaling pathways (like the MAPK/ERK pathway).
c-Src is an example of a protein that has been found to be released from the cell
membrane in response to growth factors such as PDGF. PDGF stimulated the release of
PKA from mouse Balb/c 3T3 and NRK (normal rat kidney epithelial cells) cell
membranes, resulting in increased PKA activity (deBlaquiere et al., 1994). PKA’s
release from the cell membrane and activation was found to be independent of cAMP
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(deBlaquiere et al., 1994). PDGF allowed for PDGFβ-GPCR complexes to be
endocytosed, through regulation by c-Src (Waters et al., 2005). These data demonstrate
regulatory crosstalk between these signaling pathways. There have been also reports
which have provided evidence of which PKA can modulate activity of the RTK signaling
pathway. The EGF RTK signaling pathway modulates PKA’s activity, allowing for the
understanding that the regulation occurring is bidirectional (Fishman et al., 1997).
Stimulation with EGF resulted in increases of PKA’s activity. Using an inhibitor which
acts on the EGFR, decreases in PKA’s activity were observed in the presence of the
inhibitor even with the application of EGF. It appears as though regulation of PKA
through the EGF signaling pathway occurs at the level of cAMP, as when an adenylyl
cyclase inhibitor was applied there was a large drop in PKA’s activity (Fishman et al.,
1997). The growth factor PDGF has also been shown to increase PKA’s activity,
monitored by the kinase’s ability to phosphorylate a kemptide substrate (Graves et al.,
1996). In some cases, PKA inhibits this pathway through a disruption of Ras/Raf
signaling. Raf contains a PKA consensus motif, and when Raf is phosphorylated by PKA
it does not seem to bind as well to Ras (Bornfeldt and Krebs, 1999). These, along with
other studies make it clear that crosstalk is occurring between these two canonical
signaling pathways. A continuation of this concept, in light of additional data acquired in
collaboration with Paula Deming’s lab will be revisited in Chapter 3 of this dissertation.
1.2. Significance
Understanding both SFK and PKA signaling is important given that they are
regulated in essentially every cell of vertebrates. Because of the impact these proteins
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have on many different cellular processes, its not surprising that there are multiple levels
of regulation in place in order to avoid overactive signaling. Understanding the fine
details of regulation are necessary for monitoring changes in diseased states such as
cancer. For example, Src activity is elevated in many different types of cancer, including
colon, breast, pancreatic, esophageal, ovarian, and gastric cancers (Frame, 2002).
Genetic mutations in Src are quite low, however. Truncation at codon 531 (one residue
before Y530) causing activating mutations of c-src are rare, but have been found in some
patients in advanced stages of colon cancer (Sen and Johnson, 2011). Instead, Src protein
expression and activity has been found elevated in many cancers, including breast and
colon cancer (Sen and Johnson, 2011). The catalytic activity of Src can activate signaling
pathways involved in cell growth and adhesion (Frame, 2002). SFKs are also important
for proliferation, migration, survival, motility, and invasion, all of which are necessary
for metastatic potential (Wheeler et al., 2009). The SH3 domain of Src can bind to actin.
Src can also interact with adhesion receptors like E-cadherins and integrins, affecting
cytoskeletal components (Sen and Johnson, 2011). The activity of Src could be directly
or indirectly related to interaction with receptor tyrosine kinases, such as EGFR.
Combining expression of Src and EGFR in fibroblasts has synergistic levels of tumor
production when compared to sole expression of Src and EGFR (Irby and Yeatman,
2000). Activity of Src could also be affected by the level of Csk, or the activity of
phosphatases that could dephosphorylate the C-terminal negatively regulated tyrosine
residue (Irby and Yeatman, 2000). Reduced expression of Csk could have implications
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in cancer progression, as Csk -/- embryonic mouse cells become malignant in the
presence of Src (Sen and Johnson, 2011).
SFKs could be a good target for tumors because of the many pathways the kinases
are involved in (Gelman, 2011). Small molecules can target and interfere with the kinase
domain, or prevent the SH2 and SH3 domains from adopting a conformation needed to
activate the kinase (Wheeler et al., 2009). SFK inhibitors are in pre-clinical and clinical
trials, including ATP-binding competitive inhibitors like dasatinib, bosutinib, saracatinib,
and others (Sen and Johnson, 2011). Of all the SFK inhibitors, dasatinib is the only one
that has been approved by the U.S. Food and Drug Administration for patients with
chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphocytic
leukemia (Gelman, 2011; Zhang and Yu, 2012). Dasatinib interferes with ATP binding,
and targets Bcr-Abl, SFKs, Abl, Kit, PDGFRβ, and Eph receptors (Wheeler et al., 2009)
Treating PC-3 human prostate cancer cells with dasatinib was able to suppress
proliferation, and mice injected with PC-3 cells showed tumor shrinkage in the presence
of the drug (Wheeler et al., 2009). Src inhibitors only showed small amounts of
therapeutic potential, however. Monotherapy with dasatinib had <25% benefit in Phase
II clinical trials for melanoma, prostate, and breast cancer patients (Zhang and Yu, 2012).
Combinatorial approaches may be a better answer. For example, many breast cancer
patients have overexpression of epidermal growth factor receptor 2 (HER2), which can
activate Src. In fact, around 40% of estrogen receptor breast cancers have increased Src
activity. Lapatinib is a dual inhibitor of EGFR and HER2, but there have been problems
of resistance when treating with this drug, likely due from “RTK-addicted tumor growth”
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(Zhang and Yu, 2012). A combinatorial approach with lapatinib and saracatinib (a SFK
inhibitor) seems promising to overcome resistance. Trials are still being conducted with
these approaches, but there is hope that targeting crosstalk between SFKs and RTKs
might lead to better prognosis.
Understanding the structure of SFKs is important for understanding kinase
activity, as well as protein-protein interactions (Sen and Johnson, 2011). The activating
Y416 and inactivating Y531 phosphorylation sites have proven to be highly important for
regulation of these kinases. v-Src and other activating mutants have been used to study
transforming ability, tumor progression, and metastasis (Irby and Yeatman, 2000). It’s
important to look at biomarkers for Src’s activity and genetic changes in patients with
tumors. Screening for biomarkers first can be insightful: when 23 colorectal cancer lines
were tested, all had a positive correlation with increases in Src activity (Zhang and Yu,
2012). Because of the many pathways that SFKs are involved in, it is important to
understand the fine details which regulate the kinase, as well as specific protein protein
interactions. Gaining a better understanding of these fine details could provide insight for
therapeutic targets for diseased states such as cancer. Since Src’s activity is elevated in
many different cancers, we wondered if there were other tyrosine phosphorylation events
that might be important for regulating SFK kinase activity. The goal of this dissertation
is to understand how other uncharacterized phosphorylation events in the SH2 domain
regulate SFK activity and protein binding to the kinase. We also aimed to uncover novel
signaling interactions between the SFK Fyn and the serine/threonine kinase Protein

18

Kinase A (PKA). These ideas will be addressed in Chapters 2 and 3 of this dissertation,
respectively.
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CHAPTER 2: NOVEL SITES OF SRC FAMILY KINASE
AUTOPHOSPHORYLATION REGULATE KINASE ACTIVITY AND SH2
DOMAIN BINDING CAPACITY
2.1. Literature Review
Fyn: a member of the Src Family kinases
Fyn did not originally bare the same name; it has also been named Syn and Slk.
Identified in 1986 by Semba and colleagues through molecular cloning, it was first
named Syn, or Src/Yes-related novel gene. It was found on human chromosome 6
through Southern blotting (Semba et al., 1986). The protein had 537 amino acids, and
was found to be related to Src, Yes, and Fgr. Furthermore, Fyn also had the equivalent of
Y416, the well-characterized site of autophosphorylation in Src. This site in Fyn is
numbered Y420. Later in 1986, Kawakami et al. described the same gene as Slk, or Srclike kinase. The gene was isolated from human cDNA libraries analyzed with a v-fgr
probe (Kawakami et al., 1986). Hybridization of this gene in southern blots was also
seen with v-src and v-yes probes. Sanger sequencing was performed, and sequence
analysis revealed that the positive-regulatory tyrosine in the kinase domain, as well as the
negative-regulatory tyrosine in the C-terminus, were conserved when compared to Src.
The most N-terminal region, however, was not conserved, suggesting that there were
specific functions that differ between Src and Slk (Fyn) (Kawakami et al., 1986). A
chimera was created using an active Gardner-Rasheed feline sarcoma virus plasmid
vector, which included 219 nucleotides of v-fgr. Foci formation was seen when chimeric
Slk was introduced into NIH 3T3 cells. In an immune complex kinase assay, Slk was
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able to phosphorylate tyrosine residues on IgG heavy chains similar to Src.
Novel tyrosine phosphorylation sites
Functional importance has been shown to be associated with tyrosine
phosphorylation sites in both the kinase domain, as well as the C-terminus, and these sites
have been discussed in detail in Chapter 1. However, with the phosphoproteomics
explosion in the past decade, several additional tyrosines have been found to be
phosphorylated in SFKs. This raises the question of whether these novel tyrosine
phosphorylation sites can also regulate SFKs. One novel tyrosine phosphorylation site is
located in the kinase domain (Y440) and three are located in the SH2 domain (Y185,
Y213, Y214) of Fyn. These sites have been identified a large number of times from
many different tumor types using large-scale phosphoproteomic approaches. However,
there has been little to no functional characterization of these sites. Fyn Y440 to date
does not have any site-specific studies. Y185, Y213, and Y214 each has one reported
site-specific study, further discussed below.
In the published site-specific study of Y185, primary glioblastoma cells were
transfected with either the EGF receptor or a constitutively active EGF receptor. Cells
were stimulated with EGF, underwent an α-phosphotyrosine protein IP, followed by
addition of trypsin. Tryptic peptides were subjected to mass spectrometry. In these cells,
phosphorylation of Y185 and Y420 was observed when EGFR or EGFRvIII
(constitutively active EGFR) were overexpressed (Lu et al., 2009). In a site-specific
study of Y213, the subcellular localization of Fyn was examined in liver cells. t-BHQ is
an agent that causes cellular oxidative stress. Kasper and Jaiswal identified Fyn Y213 to
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be phosphorylated via mass spectrometry on Fyn immunoprecipitated from nuclear
extracts of cells that were treated with t-HBQ for 0.5 hours. A Fyn Y213A mutant was
created, and it was found to accumulate in the nucleus in response to t-BHQ (Kaspar and
Jaiswal, 2011). The group proposed that phosphorylation of Y213 may be required for
some portion of Fyn to be exported from the nucleus. The last group studied a process
known as anergy, in which previously activated T cells go into an unresponsive state.
The study had site-specific antibodies for Fyn pY531, pY420 and pY214 (Src pY215).
There was an increase in pY124 in the anergic state, as well as pY531. Conversely, there
was a decrease in pY420 in the anergic state (Smida et al., 2007).
Although all of three of these studies have specifically identified one of the three
tyrosine phosphorylation sites that we study here, these studies provide relatively little
data toward gaining a better understanding of site-specific functionality. Here we have
used several biochemical approaches to functionally characterize the activity and
substrate binding of the three sites in the SH2 domain, providing strong evidence that
phosphorylation of the SH2 domain can disrupt its binding to proteins phosphorylated on
tyrosine. We also show evidence that suggests that tyrosine phosphorylation at Fyn Y440
reduces its kinase activity. Additionally, other large-scale phosphoproteomics studies
show that these novel tyrosine phosphorylation sites are largely conserved in other SFKs
and likely similarly regulated.
2.2. Abstract
The Src Family of tyrosine Kinases (SFKs) are important in many cellular
processes, including cell proliferation and neuronal migration. Phosphorylation is an
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essential post-translational modification that has been previously shown to regulate
kinase activity in SFKs. For many years, it has been understood that there is a
phosphorylation site that enhances kinase activity, as well as an inhibitory
phosphorylation event. These tyrosine sites are located in the kinase domain and the Cterminal regulatory domain of SFKs respectively, and have been characterized through
many site-specific studies (Yeatman, 2004). More recently, we and others have utilized
large-scale mass spectrometry based proteomic approaches to identify novel
phosphorylation sites in the SH2 (Src Homology 2) and kinase domain of Fyn that to date
have been poorly characterized. Given the importance of the SH2 domain to inter and
intramolecular interactions, we focus our study on the newly identified tyrosine
phosphorylation sites in the SH2 domain. Using in vitro and cellular approaches, we
determined that SH2 domain phosphorylation increases Fyn’s kinase activity while
simultaneously reducing its binding to other proteins. These results reveal an additional
layer of orchestrated phosphorylation that governs SFK activity and action with other
proteins. These sites are generally well conserved evolutionarily and among SFK
members. Furthermore, several other SH2 domain-containing proteins also maintain
conservation of these sites.
2.3. Introduction
For the past several decades, the catalytic activity and substrate binding of Src
Family Kinases (SFKs) has been studied due to their involvement in a wide variety of
normal and aberrant cellular processes. These enzymes are involved in many biological
processes, including development and cell proliferation. Aberrant signaling has been
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connected to disease states like cancer (Sen and Johnson, 2011). Historically, v-Src was
the first oncogene to be identified over a century ago, which further strengthens the link
these proteins have with disease (Frame, 2002). These proteins are non-receptor tyrosine
kinases, which include 11 family members. This family of kinases has been shown to
participate in signaling from G-protein coupled receptors, receptor tyrosine kinases, and
steroid receptors (Wheeler et al., 2009). SFKs share five major regulatory domains,
including an N-terminal myristoylation/lipid attachment site, a Src Homology 1 (SH1)
kinase domain, a SH2 domain, a SH3 domain, and a C-terminal region (Brown and
Cooper, 1996). Biochemical studies have identified an activating phosphotyrosine in the
kinase domain, as well as a negative-regulating tyrosine site on the C-terminus, which
when phosphorylated only allows for more basal levels of activity (Thomas and Brugge,
1997). The SH2 domains of these kinases allow for interaction with phosphotyrosines on
specific proteins for protein-protein interactions (Waksman et al., 1993). The SH3
domain allows for interaction with proline-rich regions on specific proteins (Pawson,
1995). With the increasing trend of large-scale phosphoproteomic studies over the past
ten years, other phosphotyrosine sites have also been identified on SFKs. We and others
have identified phosphotyrosine residues specifically in the SFK Fyn’s kinase and SH2
domains through a large scale proteomics approach that to date have been poorly
characterized. Site-specific approaches were taken for further characterization of these
novel phosphotyrosine sites on Fyn.
2.4. Materials and Methods
Mass spectrometry/ AQUA peptides
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The plasmid that was used for expression of SFKs in S. cervisiae was pASZ-DM, as
previously described (Grossmann et al., 2015). The yeast cells were then digested with
trypsin (Promega Cat# V511C). Desalted tryptic peptides were subjected to α-pY
(Millipore Cat # 05-321) peptide immunoprecipitation and eluted peptides were subjected
to LC-MS/MS analysis. Synthetic versions of both the unphosphorylated and
phosphorylated form of each peptide were generated by Cell Signaling Technology
(Danvers, MA). A heavy label of 7.01714 (13C6, 15N1) was added to every leucine in
order to distinguish the synthetic peptide from the native Fyn peptides in the mass
spectrometer. For the pY214 and Y214 synthetic peptides, a mass of 3.00374 (13C6, 15N1)
was added to the second glycine in the peptide in order to distinguish it from pY213 and
Y213 singly phosphorylated peptides. Low energy CID tandem mass spectra were
collected using a Thermo Electron linear ion trap (LTQ)-Orbitrap hybrid mass
spectrometer (Thermo Electron, Waltham, MA, USA). MS1 measurements were made in
the Orbitrap while fragmentation spectra were collected in the linear ion trap. Y# denotes
phosphotyrosine. * denotes the heavy label added for the synthetic version of each
peptide.
Creation of GST fusion constructs
The SH2 domain of Fyn WT and triple mutants were PCR amplified with primers that
engineer EcoRI and NotI restriction sites. Products were run on a 0.9% agarose gel and
excised, and a gel extraction was performed with the QIAEX II Gel Extraction kit
(Qiagen Cat # 20021). In separate tubes, the pGEX-4T-1 plasmid and the SH2 PCR
product were digested with EcoRI and NotI, followed by gel extractions and ligations
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with T4 DNA ligase (NEB Cat # M0202S). Ligation products were transformed into
DH5α competent cells by heat shock at 42ºC for 45 seconds, followed by icing for two
minutes. Transformed cells were streaked on LB-Ampicillin plates and incubated at 37ºC
overnight. To create GST fusion proteins for pulldown analyses, 500 ml of transformed
cultures were induced with 1 mM IPTG (UBPBio Cat # P1010-100) for 4 hours, followed
by pelleting. Pellets were resuspended in 10 ml of bacterial lysis buffer (1X PBS, 100
mM EDTA, 1 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml pepstatin) and sonicated for six
30 second blasts with 30 seconds of rest on ice in between blasts, followed by the
addition of Triton-X-100 to 1%. Insoluble material was pelleted and the supernatant was
incubated with 300 µl Glutathione resin (G biosciences Cat # 109G-C) and rocked
overnight at 4º C. The resin was washed three times with lysis buffer and once with PBS
before storage at 4º C until use.
In vitro kinase assay
GST constructs were eluted off glutathione beads with 50 mM Tris pH 8, 20 mM
glutathione, and 100 mM NaCl. 50 mM β-glycerophosphate, 10 mM Na3VO4, 100 mM
Tris pH 7.5, 100 mM MgCl2, 400 µM ATP, and 1 mM DTT were added, with either
water (-) or purified Fyn (Sigma Cat # P3042). 0.04 µg of recombinant Fyn was used for
each assay and 4-12 µg of substrate in a reaction volume of 25 µl. Kinase reactions were
incubated at room temperature for two hours, with subsequent separation using SDSPAGE. Gels were transferred onto a nitrocellulose membrane and blotted with α-GST
(Upstate Cat # 06-332), and then reprobed with α-pY (Millipore Cat # 05-321).
Purchased plasmids
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Human pRK5 c-Fyn (16032), human pRK5 DN-Fyn (16033), and human pRK5 Fyn
SH2:R176E (16035) plasmids were purchased from Addgene (Cambridge, MA, USA).
Creation of mutant full-length constructs
Full-length mutant constructs were created using the QuikChange II mutagenesis kit
(Agilent Cat # 200524). The following specific primers were used to create the indicated
Fyn mutants:
Y185D forward-5’-gaaaccaccaaaggtgccgattcactttctatccgtg-3’
Y185D reverse- 5’-cacggatagaaagtgaatcggcacctttggtggtttc-3’
Y185F forward- 5’-aaccaccaaaggtgccttttcactttctatccgtg-3’
Y185F reverse- 5’-cacggatagaaagtgaaaaggcacctttggtggtt-3’
Y213D forward- 5’-caaacttgacaatggtggagactacattaccacccg-3’
Y213D reverse- 5’-cgggtggtaatgtagtctccaccattgtcaagtttg-3’
Y213F forward- 5’-acttgacaatggtggattctacattaccacccggg-3’
Y213F reverse- 5’-cccgggtggtaatgtagaatccaccattgtcaagt-3’
Y214D forward- 5’-ttgacaatggtggatacgacattaccacccgggc-3’
Y214D reverse- 5’-gcccgggtggtaatgtcgtatccaccattgtcaa-3’
Y214F forward- 5’-gacaatggtggatacttcattaccacccgggcc-3’
Y214F reverse- 5’-ggcccgggtggtaatgaagtatccaccattgtc-3’
Y440D forward- 5’-cgaggcagccctggacgggaggttcac-3’
Y440D reverse- 5’-gtgaacctcccgtccagggctgcctcg-3’
Y440F forward- 5’-ccgaggcagccctgttcgggaggt-3’
Y440F reverse- 5’-acctcccgaacagggctgcctcgg-3’
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Y531D forward- 5’-cgacagagccccaggaccaacctggtgaa-3’
Y531D reverse- 5’-ttcaccaggttggtcctggggctctgtcg-3’
Y531F forward- 5’-cgacagagccccagttccaacctggtga-3’
Y531F reverse- 5’-tcaccaggttggaactggggctctgtcg-3’
Cell Culture/ Transfection
E1A-transformed human embryonic kidney cells (HEK 293) were grown to 70%
confluence, and then were transfected using homemade calcium phosphate (2 M CaCl2,
2X HEPES-Buffered Saline pH 7.05). After 6 hours, the cells were washed with warm
DPBS and gown for an additional 16-18 hours. Cells were lysed with 25 mM Tris pH
7.2, 137 mM NaCl, 10% glycerol, 1% NP-40 (Igepal), 25 mM NaF, 10 mM Na4P207, 1
mM Na3VO4, 1 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml pepstatin.
Hydrogen peroxide stimulation
HEK 293 cells were stimulated with 8 mM hydrogen peroxide (Sigma, Cat#216763) for
15 minutes, followed by lysis.
Western Blot Densitometry
Fyn levels were analyzed using an α-Fyn antibody (Cell Signaling, Cat # 4023). Activity
was inferred using a α-Src pY416 antibody (Cell Signaling, Cat # 6943). α-alpha tubulin
(Cell Signaling, Cat #3873) was used as a loading control. Films from western blots
were scanned, and pixel intensity was analyzed in Adobe Photoshop. After subtracting
background, mutant Fyn levels were calculated as a percentage of wild type Fyn levels
and mutant Src pY416 levels were calculated as a percentage of wild type Fyn pY416
levels. Relative levels of Src pY416 was then divided by relative levels of Fyn for each
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of the three independent experiments. Values were transformed into a Log2 ratio scale
and underwent statistical analysis using JMP Pro10 where means were compared
(ANOM Each-pair student’s t).
2.5. Results
The two canonical Fyn phosphorylation sites, Y420 and Y531, have been
identified a number of times through large-scale phosphoproteomic analyses in many
different tissue types (Figure 1A). Furthermore, the functional role of these sites has
been studied extensively through site-specific studies (Cooper and King, 1986; Cooper
and MacAuley, 1988). We have identified three phosphorylation sites in the SH2
domain: Y185, Y213 and Y214, as well as one site in the kinase domain, Y440, using a
phosphoproteomic approach of murine brain (Ballif et al., 2008). These sites have also
been identified a number of times from large scale phosphoproteomic analyses, but there
have been little to no site-specific studies. We wanted to functionally characterize these
sites further, hypothesizing that because phosphorylation of Y420 and Y531 changes
Fyn’s kinase activity, other phosphorylation sites might as well. Figure 1B depicts a
schematic of some of the conformational changes that occur in response to
phosphorylation. Under basal activity levels, Fyn is phosphorylated by Csk on its Cterminal tail at Y531 (Okada and Nakagawa, 1988). Phosphorylation of Y531 allows for
Fyn to fold up and bind to R176 in the SH2 domain, resulting in lower activity (Figure
1B, left). Dephosphorylation of Y531 permits increased SH2- and SH3- dependent
binding to other proteins as well as increased autophosphorylation of Y420, which in turn
generates a more active kinase (Figure 1B, middle). Focusing on the SH2 domain, Y185,
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Y213 and Y214 are fully conserved among vertebrates and almost completely conserved
among invertebrates (Figure 2). Furthermore, these sites are highly conserved among
SFK members (Figure 3). This suggests that phosphorylation of these sites might have
conserved functions across evolutionary time to be important in kinase regulation. We
hypothesized that phosphorylation of Y185, Y213, and Y214 could keep the kinase in a
more open conformation due to potential electrostatic repulsion (Figure 1B, right). If
Y531 normally binds to the positively charged R176 residue, this may be disrupted due to
the negative phosphates on Y185, Y213 and Y214. We therefore hypothesized that
phosphorylation of these residues would also increase the activity of the kinase.
Furthermore, we hypothesized that phosphorylation of these residues would decrease the
ability of the SH2 domain to bind to other phosphotyrosine containing proteins due to
electrostatic repulsion. Using the NMR structure of the Fyn SH2 domain, we were able
to visualize the relative proximity of Y185, Y213, ad Y214 to R176 and a pY peptide
(Figure 1C,D). Based on the NMR structure of the SH2 domain, it appears as though
R176 is not as close to Y185, Y213, and Y214 as we originally proposed. Another
possibility of what could be occurring is that phosphorylation of these residues may
disrupt the normal folding of the SH2 domain.
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Figure 1A: Fyn protein structure. Fyn structure includes the Src homology domains, along
with previously identified activating and inactivating phosphorylation sites. Y185, Y213,
Y214 and Y440 are newly identified sites. The number of times each site has been identified
as of November 2015 from large scale phosphoproteomic analyses is also indicated.
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Figure1B: Cartoon structures of SFK domains during different states of activity using Fyn
numbering. The far left cartoon depicts the kinase in an auto-inhibited, basal activation state in
which Y531 is phosphorylated by Csk. This phosphorylation allows for the binding of pY531 to
R176 in the SH2 domain, thereby folding up the kinase and making it less available to become
activated and phosphorylate its substrates. In the middle panel, autophosphorylation of Y420
increases kinase activity. Furthermore, dephosphorylation of Y531 releases autoinhibition and
allows it to better phosphorylate substrates. Certain phosphotyrosine-containing proteins can bind
to the SH2 domain, and proteins with proline rich-regions can bind to the SH3 domain. In the far
right cartoon, we propose that phosphorylation of Y185, Y213 and Y214 in the SH2 domain reduces
the amount of binding to certain phosphotyrosine-containing proteins and thereby proportionally
increases proteins bound via the SH3 domain to Fyn.
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Figure 1C, D: NMR showing two views of the SH2 domain of Fyn, along with a phosphotyrosine
peptide. Ball and stick structures highlight Y185, Y213, Y214 and R176 to show their proximity to
the phosphotyrosine binding pocket (PDB #1AOU).
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Figure 2: Sequence alignment of a portion of the Fyn SH2 domain from different species, showing
conservation of Y185, Y213, and Y214 across species. Hs= human, Mm=mouse, Rn=rat, Gg=chicken,
Xt=frog, Dr=zebrafish, Ce=worm, Dm=fly, and S1=sponge. Blue= Fyn human R176, Red= Fyn
human Y185, Y213, and Y214, respectively.
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Figure 3: Human SFK partial sequence alignment of the Fyn SH2 domain, showing conservation of
Y185, Y213, and Y214 across Src family members. Blue= Fyn human R176, Red= Fyn human Y185,
Y213, and Y214, respectively.
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Previous studies have shown that Y420 is an intermolecular autophosphorylation
site (Cooper and MacAuley, 1988). Given the novel tyrosine phosphorylation sites were
found alongside pY420 in many tumor samples, we hypothesize that Y185, Y213, Y214
and Y440 might also be autophosphorylation sites. In order to test this, we expressed
Fyn in yeast, which do not contain tyrosine-specific kinases. The yeast expressing Fyn
were digested into tryptic peptides, followed by an α-phosphotyrosine peptide IP and
analysis with LC MS-MS. Synthetic versions of both the phosphorylated and
unphosphorylated peptides were used as a reference. Comparison with the synthetic
peptides revealed that Fyn autophosphorylates at Y185, Y213, Y214, and Y440 (Figures
4-7). Y420 was also found to be autophosphorylated as a control (Figure 8).
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Figure 4: Fyn Y185 is autophosphorylated as confirmed by mass spectrometry. A: Phosphorylated
GAY#SLSIR peptide (pY185) found to be autophosphorylated in yeast. # denotes phosphorylation.
B: A synthetic version of the phosphorylated GAY#SL*SIR peptide. A * indicates a heavy label on
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Figure 5: Fyn Y213 is autophosphorylated as confirmed by mass spectrometry. A: Phosphorylated
LDNGGY#YITTR peptide (pY213) found to be autophosphorylated in yeast. # denotes
phosphorylation. B: A synthetic version of the phosphorylated L*DNGGY#YITTR peptide. *
indicates a heavy label on leucine. C: A synthetic version of the unphosphorylated
L*DNGGYYITTR peptide. * indicates a heavy label on leucine. Red and blue stars in fragment ion
tables indicate identified b and y ions.
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Figure 6: Fyn Y214 is autophosphorylated as confirmed by mass spectrometry. A: Phosphorylated
LDNGGY^Y^ITTR peptide (pY213 and pY214 mixture) found to be autophosphorylated in yeast. ^
denotes phosphorylation. B: A synthetic version of the phosphorylated L*DNGG*YY#ITTR peptide.
* indicates a heavy label on leucine and glycine. C: A synthetic version of the unphosphorylated
L*DNGGYYITTR peptide. * indicates a heavy label on leucine. Red and blue stars in fragment ion
tables indicate identified b and y ions.
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Figure 7: Fyn Y440 is autophosphorylated as confirmed by mass spectrometry. A: Phosphorylated
WTAPEAALY#GR peptide (pY440) found to be autophosphorylated in yeast. # denotes
phosphorylation. B: A synthetic version of the phosphorylated WTAPEAAL*Y#GR peptide. *
indicates a heavy label on leucine. C: A synthetic version of the unphosphorylated
WTAPEAAL*YGR peptide. * indicates a heavy label on leucine. Red and blue stars in fragment ion
tables indicate identified b and y ions.
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Figure 8: Fyn Y420 is autophosphorylated as confirmed by mass spectrometry. A: Phosphorylated
LIEDNEY#TAR peptide (pY420) found to be autophosphorylated in yeast. # denotes
phosphorylation. B: A synthetic version of the phosphorylated L*IEDNEY#TAR peptide. *
indicates a heavy label on leucine. C: A synthetic version of the unphosphorylated L*IEDNEYTAR
peptide. * indicates a heavy label on leucine. Red and blue stars in fragment ion tables indicate
identified b and y ions.
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In order to determine further whether sites in the SH2 domain were
autophosphorylated, and specifically if they could be intermolecularly
autophosphorylated, an in vitro kinase assay was performed with purified components
(Figure 9). GST fusion constructs were engineered to contain solely the SH2 domain
of Fyn as a wild type (WT) molecule or as one that harbored phenylalanine
substitutions in the 185, 213 and 214 residues. These were eluted from the glutathione
resin used to purify them and used as a substrate for full-length purified Fyn in an in
vitro kinase assay. Phosphorylation was robustly observed in the WT SH2 domain.
However, when the three sites in the SH2 domain were mutated to a phenylalanine, the
amount of phosphorylation was drastically reduced. Phosphorylation on soluble GST
alone was not observed. These results show Fyn is capable of intermolecular
autophosphorylation in the SH2 domain, largely at tyrosines 185, 213, and 214.
However, there was still some residual tyrosine phosphorylation observed, indicating
that there are other site(s) that are being phosphorylated in the SH2 domain. Three
other tyrosine residues lie within the SH2 domain of Fyn. Only one of these three other
tyrosine residues has been identified to be phosphorylated by mass spectrometry.
Phosphotyrosine 150 has been identified four times by mass spectrometry in rat tissue,
with no site-specific studies. One potential reason for such a low number of
identifications of pY150 could be because it falls within a large tryptic peptide, which
could lead to more difficult identification on the mass spectrometer. However, based
on mass spectrometry identification it appears as though Y150 could be
phosphorylated, but this has not been confirmed in human tissue samples. Another
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tyrosine, Y203, has not been identified to be phosphorylated by mass spectrometry.
This could be due in part to the fact that this tyrosine falls within a small tryptic
peptide, which could also lead to detection difficulties. The only other tyrosine in the
SH2 domain (other than the three that we have further characterized) is Y231, which
has not been identified to be phosphorylated by mass spectrometry. Like Y150, this
Y231 also falls within a large tryptic peptide, which can lead to difficulties in
identification. Therefore, although there does seem to be residual phosphorylation
when Y185, Y213, and Y214 are mutated to phenylalanies, issues with tyrptic peptide
length could be the reason for poor identification. Y150, Y203, and Y231 are
highlighted in Figure 10, along with their potential tryptic peptides.
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Figure 9: Fyn Y185, Y213, and Y214 are the main sites of autophosphorylation in the SH2 domain.
In vitro kinase reaction with or without soluble, purified, active Fyn and soluble, purified GST or
GST-Fyn-SH2 (wildtype or with Y to F substitutions at Y185, Y213 and Y214). Kinase reactions were
separated by SDS-PAGE and blotted with the indicated antibodies. Molecular weight markers at left
are in kDa.
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Human&Fyn&
MGCVQCKDKEATKLTEERDGSLNQSSGYRYGTDPTPQHYPSFGVTSIPNYNNFHAAGGQG&
LTVFGGVNSSSHTGTLRTRGGTGVTLFVALYDYEARTEDDLSFHKGEKFQILNSSEGDWW&
EARSLTTGETGYIPSNYVAPVDSIQAEEWYFGKLGRKDAERQLLSFGNPRGTFLIRESET&
TKGAYSLSIRDWDDMKGDHVKHYKIRKLDNGGYYITTRAQFETLQQLVQHYSERAAGLCC&
RLVVPCHKGMPRLTDLSVKTKDVWEIPRESLQLIKRLGNGQFGEVWMGTWNGNTKVAIKT&
LKPGTMSPESFLEEAQIMKKLKHDKLVQLYAVVSEEPIYIVTEYMNKGSLLDFLKDGEGR&
ALKLPNLVDMAAQVAAGMAYIERMNYIHRDLRSANILVGNGLICKIADFGLARLIEDNEY&
TARQGAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELVTKGRVPYPGMNNREVLEQVE&
RGYRMPCPQDCPISLHELMIHCWKKDPEERPTFEYLQSFLEDYFTATEPQYQPGENL&
&
Figure 10: Other potential phosphotyrosines in Fyn’s SH2 domain. Full length sequence of
human Fyn. The SH2 domain is highlighted in blue. Y150, Y203, and Y231 are highlighted in
yellow. Potential tryptic peptides are underlined.
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We formulated working hypotheses in regards to the effects of these novel
phosphorylation sites based on their location in the kinase and SH2 domains. In the
kinase domain, there didn’t appear to be a straight-forward way to predict the effect of
phosphorylation at Y440. It could act synergistically with phosphorylation at Y420 and
thereby increasing Fyn’s activity. Alternatively, it might alter the structure of the
activation loop and thereby reduce its phosphorylation or the kinase’s stability after Y440
is phosphorylated. Investigation of Fyn Y440 was employed with non-phosphorylatable
and phosphomimetic mutants. Y440D exhibited lower amounts of α-Src pY416, an
antibody used as a proxy for kinase activity, compared to WT and Y440F (Figure 11A).
The lower activity observed in the Y440D mutant was statistically different from WT, as
well as the Y440F. The activity of the Y440F mutant, however, was not statistically
different from WT (Figure 11B). Regarding Y185, Y213 and Y214 phosphorylation we
predicted that phosphorylation of these residues may leave the kinase in a more open
conformation, thereby increasing its activity. In order to test this hypothesis, we created
both single as well as triple phosphomimetic mutants (replacing a tyrosine with an
aspartic acid) of Y185, Y213, and Y214 (3D). It has been shown in the literature that a
Y531F mutation increases kinase activity compared to Fyn WT (Piwnica-Worms et al.,
1987). Therefore, a Y531F mutant was also created as a positive control for increased
kinase activity. Experiments were also performed in which transfected Fyn WT and
mutants were blotted for α-Src pY416 as a proxy for activity (Figure 11C). The Fyn 3D
mutant showed activity levels higher than the WT and more comparable to Y531F, both
of these values were statistically different from WT. (Figure 11D).
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Figure 11: Mutation mimicking a negative charge of residue 440 decreases kinase activity. Mutations
mimicking a negative charge of residues 185, 213, and 214 increases kinase activity. A: Transfections
were performed on HEK 293 cells using either full length Fyn WT, Y440D or Y440F full-length
DNA. Whole cell extracts were blotted with α-Fyn pY416 as a proxy for Fyn cellular activity, as well
as α-Fyn for total levels and α-alpha tubulin. B: Fold change of Y440D or F mutants compared to
WT Fyn. * indicates statistical difference. C: Transfections HEK 293 cells using either full length
Fyn WT, Y3D, Y531F, or KD full-length DNA. Whole cell extracts were blotted with α-Fyn pY416,
as well as α-Fyn for total levels and α-alpha tubulin. D: Fold change of Y3D, Y531F, and KD
mutants compared to WT Fyn. * indicates statistical difference.
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Given these results we predicted that mutation of these residues to an aspartic acid would
increase the kinase’s ability to phosphorylate cellular substrates. Cells were transfected
with either single or Y3D Fyn mutant constructs and blotted for α-phosphotyrosine to
observe total phosphorylation levels (Azam et al., 2008) (Figure 12A). When compared
to Fyn WT, phosphomimetic mutants showed a marked increase in total tyrosine
phosphorylation levels (measured above the pY Fyn bands). Single mutants in the SH2
domain also had higher averages in cellular pY levels compared to WT, but they were not
statistically different (Figure 12B).
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Figure 12: Single and triple Y/D SH2 mutants increase kinase activity. A: HEK 293 cells were
transfected with kinase dead (KD) wild type (WT) or Y/D mutants of Fyn. Whole cell extracts were
blotted with α-phosphotyrosine as a proxy for Fyn cellular activity, or with the indicated antibodies.
B: Fold change of single and tripe Y/D mutants compared to WT Fyn. * indicates statistical
significance. Credit: Jackie Mann, Paula Deming
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We also hypothesized that phosphorylation of Y185, Y213, and Y214 would
decrease the ability of the SH2 domain to bind to phosphotyrosine residues of certain
proteins due to disruption of the SH2 domain structure or through electrostatic repulsion.
Pulldown assays were performed to monitor the binding of the SH2 domain to both a
specific known SH2 binding partner (ESDN), as well as the binding of a cellular extract
with high levels of tyrosine-phosphorylated proteins. In order to observe whether the
total amount of proteins bound to the SH2 domain changed based on phosphorylation
status, hydrogen peroxide-stimulated HEK 293 cell lysates were incubated with either
WT, 3D, or R176E SH2-GST constructs. Hydrogen peroxide is a potent tyrosine
phosphatase inhibitor, and is used in these studies to increase the total amount of tyrosine
phosphorylation in the cell prior to lysis. Fyn SH2 WT showed a pool of proteins bound,
but this binding was absent in the 3D and R176E SH2-GST constructs (Figure 13A).
While tyrosine-to-glutamate mutations suggest functional consequences of
phosphorylation, a glutamate is not a phosphate. Therefore, we devised an approach to
test if phosphorylation of the SH2 domain by Fyn would disrupt binding of a known FynSH2 domain binding partner. ESDN is a known phosphotyrosine-dependent Fyn SH2
binding partner (Aten et al., 2013), and was added to the Fyn SH2 domain in the
pulldown assay as a constituent of a protein extract from cells stimulated with hydrogen
peroxide (Figure 13B). When wild type SH2-GST was incubated in an in vitro kinase
assay with full-length purified Fyn, this reduced the amount of ESDN that bound to the
SH2 domain, even though there were relatively even levels of GST. These data support
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the hypothesis that phosphorylation of these residues decreases the protein’s ability to
bind to phosphotyrosines on specific targets.
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Figure 13: Fyn SH2 domain phosphorylation decreases substrate binding. A: HEK 293 cells were
stimulated with hydrogen peroxide, a tyrosine phosphatase inhibitor. Lysates were incubated with
either Fyn SH2 WT, 3D, or R176E-GST beads for a pulldown assay. Blots were probed for both αpY and α-GST. B: Schematic for method used to test binding to a known Fyn substrate. GST-FynSH2 was subjected to an in vitro kinase assay with or without purified Fyn. Lysates containing a
known binding partner, ESDN, where then subjected to a pulldown analysis.
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Due to the high amount of conservation among the SFKs, we wondered if these
sites were conserved in other proteins that contained SH2 domains. Indeed, there is a
relatively high amount of conservation of these residues among other proteins that
contain SH2 domains (Figure 14). This suggests that regulation of homologous sites may
extend to non-SFK SH2 domains. We compared the number of SH2 domains which had
one or more of the three tyrosines conserved with data from Phosphositeplus (Cell
Signaling Technology, Danvers, MA, USA) which curates known phosphorylation sites.
Strikingly, a far greater number of these conserved sites were found phosphorylated if
they were also part of a protein with a kinase domain. This suggest that while SH2
domain regulation at these sites is possible by heterologous kinases, the majority of
phosphoregulation at these sites is via autophosphorylation (Figure 14).
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Figure 14: Homologous residues to at least one of Tyr185, Tyr 213 or Tyr214 are found in 81 of the
120 human SH2 domains. Gene products with both a kinase domain and a SH2 domain are 2.8 times
more likely to have tyrosines phosphorylated at the equivalents of Tyr185, Tyr213 or Tyr214 than
gene products with SH2 domains but without a kinase domain (18/22 (82%) compared with 17/59
(29%)).
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2.6. Discussion
We have now provided evidence that phosphorylation of Y185, Y213 and Y214
alters the kinase’s activity and the ability of the SH2 domain to bind tyrosine
phosphorylated targets. A decrease in SH2 binding partners could be due to electrostatic
repulsion. Another possibility is that phosphorylation of these residues allows for a
conformational change that decreases the ability for specific phosphotyrosine containing
proteins to bind to the SH2 domain. We also show that Y185, Y213, Y214 and Y440 are
sites of autophosphorylation through a proteomics approach. Furthermore, the three sites
in the SH2 domain were shown to be autophosphorylated through an in vitro kinase
assay. Mutation of these sites greatly reduced the amount of autophosphorylation in the
SH2 domain. However, there was still a small amount of phosphorylation observed when
the three sites were mutated to phenylalanines, suggesting that there is at least one other
site that is phosphorylated in the SH2 domain. There are several other tyrosine residues
in the SH2 domain that could be possible phosphorylation candidates. Phosphomimetic
mutants of Y185, Y213, and Y214 showed an increase in both the total levels of
phosphotyrosine, as well as phosphorylation of Src pY416 compared to the WT.
Although it is only a phosphomimetic, these results suggest that a negative charge on
these residues is able to increase the overall activity of the kinase. Y440D mutants
showed a decrease in Src pY416 compared to WT and Y440F. One potential reason
could be that a negative charge on this residue could be obstructing the phosphotransfer
interaction that is occurring at Y420, thereby decreasing activity. Interestingly, in recent
reports, additional sites of phosphorylation in or near the activation loop of Erk2 reduced
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its kinase activity or substrate binding and phosphorylation (McReynolds et al., 2016).
Binding of ESDN is reduced when the Fyn SH2 domain is phosphorylated in vitro. Total
protein binding to the Fyn SH2 domain is absent when Y185, Y213, and Y214 were
mutated to aspartic acids. The negative charge could be repulsing negative phosphates on
phosphotyrosines attempting to bind to the SH2 domain of Fyn.
From these results we have developed a proposed model of what might be
happening during various Fyn phosphorylation states. One possibility of why the
phosphorylation of these residues in the SH2 domain could be for the release of binding
partners so that Fyn is able to travel to another area of the cell and interact with a nonSH2 target. However, as will be discussed in the Appendix of this dissertation, our
immunofluorescence data of Fyn wildtype and Y3D do not appear to show significantly
different subcellular localization. Another possibility is that there is a switch in
preference, or at least proportion, to SH3 binding partners, allowing for their subsequent
phosphorylation. Yet another possibility is that all of these phosphorylation events are
forms of negative feedback that work to participate in turning off a given stimulation.
Further biochemical studies will be employed in the future to test whether there is a
change in SH3 preference based on specific phosphorylation states or whether these sites
participate as part of a negative feedback mechanism. Detailed experiments to test this
hypothesis are outlined in Chapter 4 of this dissertation.
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CHAPTER 3: Novel signaling crosstalk between Src Family Kinases and PKA
3.1. Literature Review
Historical Prospective: Initial identification of components of the PKA signaling pathway
The G-protein coupled receptor signaling pathway is one of the most highly
studied signaling pathways in the biochemical field. Many early studies helped
contribute to the heart of this pathway, and led to several Nobel Prize awards. This
section touches on some of the main points that were found along the way which helped
shape the signaling pathway that is currently accepted. Initially, it was not understood
how an agonist on the outside of the cell could lead to higher cAMP levels on the inside
of the cell (Beavo and Brunton, 2002). Birnbaumer and Rodbell’s studies found that
GTP was necessary for this process to occur, with later work identifying G proteins.
Techniques such as cloning and protein purification helped identify a family of small G
proteins, that associated with what were termed G protein-coupled receptors. The classic
G protein subunits identified were called Gα subunits and Gβγ subunits. In 1957, it was
found that the cyclic nucleotide cAMP is a second messenger to adrenaline (Beavo and
Brunton, 2002) . By 1958, adenylyl cyclase and phosphodiesterase activities were
understood. Krebs and others found that adrenaline is able to activate kinase signaling
cascades. The first protein in this cascade was termed phosphorylase-kinase kinase.
cAMP was able to directly activate it, and the protein was subsequently renamed cAMPdependent protein kinase or protein kinase A.
Throughout the 1960’s and 1970’s, much research focused on characterizing the
signaling roles of cAMP. In 1981, Seamon and Daly identified forskolin, a reagent that
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was used to increase the amount of cAMP within the cell. This compound is still used
today as a powerful tool in the world of signaling. Forskolin is a diterpene found in the
roots of the Indian plant Coleus forskholii (Seamon et al., 1983). This compound
activates the enzyme adenylyl cyclase, a transmembrane protein which is able to convert
ATP into cAMP. Forskolin can act on adenylyl cyclase in a direct manner, and does not
require hormone receptors or G proteins. Adenylyl cyclase contains two domains, C1
and C2, which are situated as mirror images to one another (Insel and Ostrom, 2003).
The C1 domain has a catalytic and Gi binding site (a G-protein α subunit which inhibits
the formation of cAMP from ATP). The C2 domain has a Gs binding site and a
“pseudocatalytic” area (Insel and Ostrom, 2003). Forskolin interacts with the C2 domain
of adenylyl cyclase and can activate it, allowing the enzyme to convert ATP to cAMP
(Seamon et al., 1983). Activation of adenylyl cyclase occurs quickly and can be
reversed. Derivatives of this compound can also activate adenylyl cyclase, but not as
strongly as forskolin.
In 1968, Krebs and others isolated a cAMP-dependent protein kinase from rabbit
skeletal muscle (Walsh et al., 1968). This kinase was able to phosphorylate casein and
protamine as measured through the transfer of 32P from 32P-γATP. Both of these events
were dependent on the presence of cAMP. Furthermore, the isolated protein kinase was
able to phosphorylate and increase the activity of phosphorylase kinase. Due to this
occurrence, the new protein was initially termed phosphorylase kinase kinase.
Subsequent studies by Tao and others were able to purify the kinase from rabbit
reticulocytes by DEAE-cellulose chromotography and characterize it using biochemical
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methods (Tao et al., 1970). Tao et al. concluded that the kinase contained two subunits,
one which bound to adenosine 3’,5’-cyclic monophosphate (cAMP), and a catalytic
subunit. cAMP dissociates the two components by binding to the inhibitory portion of
the kinase (Tao et al., 1970). Due to these characteristics, this protein is termed a
holoenzyme in that it is made up of multiple subunits.
The catalytic subunit of PKA was later purified from rabbit skeletal muscle
(Bechtel et al., 1977). DEAE-cellulose chromatography identified two forms of the
kinase based on time eluted from the chromatography process, termed type I and type II,
respectively. Catalytic subunits isolated from either of these peaks had the same protein
properties, suggesting that it was the same protein. Characterization of this subunit
determined that the catalytic portion appears to be a monomer once it dissociates from the
holoenzyme (Bechtel et al., 1977). Bechtel and others were able to determine the
properties of the catalytic subunit using several biochemical methods. Electrophoresis
and sedimentation equilibrium experiments were performed to determine the catalytic
subunit’s approximate molecular weight. Isoelectric focusing and amino acid
composition were also determined. Interesting findings included that the subunit had
large amounts of phosphate bound. Furthermore, enzymatic properties of the
holoenzyme in the presence of cAMP were the same as the catalytic subunit alone. A
great deal of work in the 1970’s was able to formulate that cAMP-dependent protein
kinases are comprised of two regulatory subunits and two catalytic subunits (Taylor et al.,
1976). When these subunits are together, they exist as an inactive complex. Binding of
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cAMP to the regulatory subunit allows for dissociation and subsequent activation of the
catalytic subunit.
Holoenzyme composition and AKAPs
Throughout the early 1970’s, regulatory and catalytic subunits began to be
purified. In 1976, Taylor and colleagues were able to isolate the native holoenzyme
complex from pig muscle with affinity column purification (Taylor et al., 1976). Within
the holoenzyme structure there are three genes that encode the catalytic subunit: Cα, Cβ,
and Cγ (originally characterized in mouse). Four genes encode the regulatory subunit:
RIα, RIβ, RIIα, and RIIβ (originally characterized in porcine skeletal muscle) (Michel
and Scott, 2002). The regulatory subunits of PKA form dimers through a dimerization
domain contained on the protein, whereas the catalytic subunits exist as monomers.
There are two types of PKA heterotetrameric holoenzymes; type I contain RIα and RIβ
dimers, while type II contain RIIα and RIIβ dimers. Type I PKA is predominately
cytoplasmic, while type II is mostly located at specific organelles within the cell. PKA
has been extensively studied in its ability to be transported to specific regions of the cell
by AKAPs (A-kinase anchoring proteins), creating distinct pools of the protein (Beavo
and Brunton, 2002). There are over 50 proteins that have been classified as AKAPs,
most of which interact with the type II class of PKA.
Crosstalk between receptor tyrosine kinase and G-protein coupled receptor pathways
Initially described as separate signaling pathways, growing evidence over the past
several decades has provided the idea that there is crosstalk between the canonical
receptor tyrosine kinase (RTK) and G-protein coupled receptor (GPCR) pathways. In
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classic growth factor/ receptor tyrosine kinase signaling, the binding of growth factors
allows for receptor dimerization and subsequent trans-autophosphorylation of the
receptor. SH2 and PTB domains of certain proteins can bind downstream, including
Grb2. Binding of Grb2 causes the initiation of signaling cascades that ultimately leads
to the activation of the MAPK pathway, which has classically been described as distinct
from the GPCR/ PKA signaling pathways of cell proliferation. However, Shc, a protein
that can associate with the Grb2 and SOS complex, has been shown to have an increase
in tyrosine phosphorylation when Gβγ was expressed (van Biesen et al., 1995). There
was also an increase in Shc’s association with Grb2, as well as increases in MAPK
activity with Gβγ expression.
Another G protein subunit, Gsα, has been shown to be tyrosine phosphorylated
by the EGFR (Poppleton et al., 1996). Phosphorylation of Gsα by the EGFR resulted in
a two fold increase of adenylyl cyclase activity (Poppleton et al., 1996). The Gsα
subunit has also been found to be phosphorylated in vitro by pp60c-src (Src) on Y37 and
Y377 (Moyers et al., 1995). The sites were initially identified using Edman
degradation techniques, and confirmed to be substrates of c-Src with synthetic peptides
which contained these residues. This was observed through the ability of the synthetic
peptides to be phosphorylated during an in vitro kinase reaction with immunecomplexed c-Src. These phosphorylation events increased the binding of the Gsα
protein to GTP. Y37 lies in proximity to where the βγ subunit binds to Gsα. Y377 is
close to where the β-adrenergic receptor can interact with Gsα, and phosphorylation
may alter this interaction (Moyers et al., 1995). The location of each of these tyrosine
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phosphorylation events could potentially affect binding interactions of Gsα,
subsequently affecting the protein’s activity. These studies are just a few of many
different lines of evidence providing implication of crosstalk between these two
signaling pathways.
Specific interactions between PKA, RTKs, and the SFK Fyn
It has been well-established in the literature that growth factors are able to
activate PKA, and that PKA signaling occurs downstream of RTK signaling. However,
the exact mechanisms that occur between RTKs and PKA are still not fully understood.
Based on previous studies indicating interactions between growth factor receptors and
PKA (see Chapter 1 of this dissertation), further studies determined that the catalytic
subunit of PKA can be phosphorylated by EGFR and PDGFRβ on Y330. This was
identified through in vitro kinase assays and cellular stimulations, and as a readout mass
spectrometry as well as a phosphospecific antibody to pY330 (Caldwell et al., 2012).
Y330 is located near the C-terminus of PKA-c, close to the substrate binding pocket of
the kinase. Phosphorylation of this residue regulated the activity of PKA in vitro by
altering the km, indicating better substrate binding. Furthermore, stimulation with EGF,
PDGF, and FGF lead to PKA-c phosphorylation, specifically at Y330. Phosphorylation
of this amino acid could potentially cause further signaling through interactions with
proteins containing SH2 and PTB domains.
Crosstalk between PKA and SFKs has also been studied. Serine
phosphorylation has been investigated in Src, although not as extensively as tyrosine
phosphorylation in regards to the protein’s regulation. Serine 17 was found to be the
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main site of serine phosphorylation on the protein (Brown and Cooper, 1996).
Furthermore, this site was recognized to be a PKA consensus motif. Treatment with
forskolin increased Src’s activity, as observed through α-Src pY416 western blotting
(Schmitt and Stork, 2002). Mutagenesis of S17 to an alanine removed PKA-induced
phosphorylation, as well as decreased Src’s activity. Adrenergic signaling has also been
shown to lead to phosphorylation of Src S17, resulting in tumor progression in ovarian
cancer cells as measured by an invasion assay (Armaiz-Pena et al., 2013). The PKA
target RxxS motif in the N-terminal region of the Src protein is conserved in Fyn, Hck,
Lck, Fgr and Blk (Yeo et al., 2011). Serine 21 of Fyn was studied further due to
conservation of this PKA target motif. Yeo et al. found that PKA is able to
phosphorylate Fyn on serine 21, which allows for increases in Fyn’s kinase activity.
Mutation of the serine residue to an alanine decreases phosphorylation of Fyn by PKA, as
well as Fyn’s kinase activity. Cells expressing a S21A mutant also showed slower
migration compared to WT in a wound healing assay (Yeo et al., 2011). Collectively,
these data demonstrate how crosstalk is occurring between SFKs and PKA.

3.2. Abstract
Protein kinase A (PKA) is a serine/threonine kinase involved in many cellular
processes, including migration and proliferation. PKA and the tyrosine kinase Fyn have
been previously shown to mutually phosphorylate each other, thereby regulating PKA
and Fyn activity. PKA and Fyn also colocalize when visualized with
immunofluorescence and are physically complexed together in cells as assessed by co71

immunoprecipitation. We hypothesized that Fyn and PKA collaborate to regulate a
distinct set of proteins, which could include scaffold proteins or other signaling
molecules. To test this and to identify interacting partners influenced by Fyn, we
immunoprecipitated PKA-c from cells grown in Stable Isotope Labeling of Amino Acids
in Cell Culture (SILAC) media with or without overexpressed active or kinase-dead Fyn.
The proteins in the immune complexes were separated by SDS-PAGE, and subjected to
in-gel digestion. Extracted tryptic peptides were subjected to liquid chromatographytandem mass spectrometry to identify and quantify PKA binding partners that were
dependent on Fyn overexpression or kinase activity. Several statistically significant Fynenhanced binding partners were found. Further biochemical analysis validated and
characterized some of these distinct signaling complexes.

3.3. Introduction
PKA is a serine/threonine kinase that is involved in many important cellular
processes, including proliferation, differentiation, and migration (Kannan et al., 2007).
Likely due to a need to maintain temporal and spatial control of its activity to effectuate a
wide variety of processes, many proteins have evolved to regulate PKA’s activity, as well
as its localization within the cell. PKA and Src Family Kinases (SFKs) are best known
for their separate canonical signaling pathways. However, research primarily conducted
over the past two decades has uncovered crosstalk between the two kinases. PKA has
been shown to be downstream of receptor tyrosine kinases, and is phosphorylated on
Y330 in response to growth factor stimulation (Caldwell et al., 2012). Furthermore,
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when Y330 was mutated to a phenylalanine, some residual phosphorylation was observed
(unpublished observations, Deming). This suggested that there were other sites of growth
factor-induced tyrosine phosphorylation on PKA. Research has also shown that PKA
phosphorylates Fyn on Ser 21, which increases Fyn’s kinase activity (Yeo et al., 2011).
Furthermore, unpublished work from Paula Deming’s lab showed that overexpression of
Fyn increased levels of PKA activity as measured by blotting whole cell extracts with a
phosphomotif-specific antibody for the PKA consensus phosphorylation motif. From
these data it was hypothesized that Fyn could also be directly phosphorylating and
activating PKA. Through the use of mass spectrometry and comparison to a synthetic
AQUA peptide (Cell Signaling Technology, Danvers, MA) we identified PKA Y69 as a
Fyn phosphorylation site (P. Deming, M. Weir, B. Ballif, unpublished). Recently,
important biological implications for this cross-talk between PKA and the SFK member
Src was shown to lead to mammary tumorogenesis in mice (Beristain et al., 2015). Coinvolvement of PKA and SFKs in such disease states heightens the necessity to better
understand the new signaling pathway between these proteins. From these data we
hypothesized that co-activation of Fyn and PKA will lead to binding partners that would
further the signaling pathway. Because these binding partners have not yet been
identified, we aimed to uncover them through a proteomics approach.
3.4. Materials and Methods
Plasmids used for transfections
The PKA-c-YFP plasmid (cloned into pCDNA3 (Invitrogen) as Hind III/Xba I
fragments) was a gift from M. Zaccolo from the University of Padua, previously
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described (Zaccolo and Pozzan, 2002). Fyn constructs were both purchased from
Addgene (Cambridge, MA, USA): human pRK5 c-Fyn (16032) and human pRK5 DNFyn (16033).
Co-immunoprecipitations
HEK 293 cells were transfected using polyethylenimine (PEI) with empty vector, Fyn
WT, or Fyn KD and serum starved for 24 hours, followed by harvesting after another 24
hours (total growth was 48 hours). 2 mg of lysates were immunoprecipitated with 2 µg
α-PKACα. Immunoprecipitates were subjected to SDS PAGE electrophoresis and
immunoblot analysis for for α-PKACα (Santa Cruz Cat# sc-903), or α-Fyn (Santa Cruz,
Cat# sc-16).
α-phospho-PKA substrate western blots
Cells were transfected using PEI with pcDNA3.1 empty vector, Fyn WT, or Fyn KD.
Cells transfected with empty vector were either untreated or stimulated with 30 µM of
Forskolin (EMD Millipore, Cat# 44428-5MG) for fifteen minutes. Whole cell extracts
were subjected to SDS PAGE electrophoresis and immunoblot analysis for α-phosohoPKA substrate (Cell Signaling, Cat# 9624), α -Fyn (Santa Cruz, Cat# sc-16) or α-Actin
(Santa Cruz, Cat# sc-1615-R).
Immunofluorescence microscopy and FIJI image analysis
HEK 293 cells were grown in 6 well plates with glass coverslips to 70% confluence,
followed by calcium phosphate transfection (Promega, Cat# E1200). Cells were
transiently transfected with one or several plasmids encoding: Fyn WT, Fyn KD, and
PKA-c-YFP. For calcium phosphate transient transfections, the precipitate was incubated
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on the cells for six hours, followed by a wash with warm 1X phosphate buffered saline
(PBS) and replacement of DMEM media (10% fetal bovine serum/cosmic calf serum
mixture). Cells grown on glass coverslips were fixed with 3.7% paraformaldehyde for 10
minutes, with a subsequent gentle wash of PBS. Slides were then incubated with
permeant containing 0.5% Triton-X-100 for 10 minutes, followed by a gentle wash with
PBS. Incubation with α-Fyn (α-Rabbit, Santa Cruz, Cat# sc-16) was performed at room
temperature for one hour in 1.5% BSA in PBS at a 1:500 dilution. Slides were washed
five times, each for five minutes, with PBS. Alexa 555 (α-Rabbit, CST Cat# 4413S)
secondary at a 1:5,000 dilution was added for 45 minutes at 4° in 2% BSA in PBS. Cells
were washed five times with PBS and mounted with DAPI hardset (Vectashield, Cat #
14-1500). Slides were imaged using a Nikon Eclipse Ti inverted microscope with a 40X
objective and 2X zoom to generate 80X images. RGB images were generated in Adobe
Photoshop. Original nd2 files generated from the confocal microscope were opened in a
plugin of ImageJ (FIJI) to perform colocalization studies. 30 cells were outlined with the
draw tool, and red and green channels were compared to each other using Coloc2. For
each condition, 30 cells were selected to compare red (Fyn) and green (PKA-c-YFP)
channels. Spearman’s rank correlation values were put into GraphPad Prism to generate
box and whiskers plots with a 5-95 percentile setting. Mean Costes P values and standard
deviations were also calculated, with the statistical significance of these tests represented
by a P value of 0.95 or higher (Costes et al., 2004).
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SILAC (Stable Isotope Labeling of Amino Acids in Cell Culture) and mass spectrometry
HEK 293 cells were grown in either light or heavy labeled media. Light media
contained unlabeled arginines and lysines (MP Biomedicals, arginine Cat# 194626, lysine
Cat# 194696). Heavy media contained arginine and lysine with C13 and N15 isotopes of
carbon and nitrogen respectively (Cambridge Isotopes, arginine Cat # CNLM-539-H-1,
lysine Cat# CNLM-291-H-1). HEK 293 cells were transfected using polyethylenimine
(PEI) with empty vector, PKA-c-YFP, Fyn WT, or Fyn KD and serum starved for 24
hours, followed by harvesting after another 24 hours (total growth was 48 hours). Cells
were lysed in 25 mM Tris pH 7.2, 1% Igepal, 137 mM NaCl, 25 mM NaF, 1 mM sodium
pyrophosphate, 1 mM DTT (dithiothreitol), HALT protein inhibitor cocktail, 1 mM
sodium othrovanadate, and 10% glycerol, followed by immunoprecipitation of 8 mg
whole cell extract with 2 µg α-GFP (Life Technologies, Cat# A11122). Light and heavy
samples were combined following immunoprecipitation and eluted proteins were run on a
10% separating (37.5:1 acrylamide: bisacrylamide) SDS-PAGE gel. After staining with
coomassie, lanes were divided into fourteen sections, cut out and diced to 1 mm cubes
and these cubes were subjected to in-gel digestions with trypsin (Promega, Cat# V511C).
Following extraction, peptides were subjected to reverse-phase liquid chromatography
using a column packed with 12 cm of magic C18 resin. Data were collected using an MS1
precursor scan in the Orbitrap followed by ten MS2 data-dependent scans (from the MS1)
in the LTQ XL. Spectra were searched against a forward and reverse human database
with a 30PPM cutoff, with static modifications of 71.037 for cysteine, as well as
differential modifications of 10.008 for arginine and 8.014 for lysine. A linear
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discriminator of 0.9 (10% false discover rate) was first used and subsequently filtered
allowing only for proteins with 3 or more unique peptides. Peptides were removed which
were also found in the empty vector control lanes, as well as the following contaminants
from the Fyn versus no Fyn experiment: Igkc, Flg2, and SCGB2A1. Peptide
quantification was performed using VISTA
(http://www.ncbi.nlm.nih.gov/pubmed/?term=18798661) on peptides obtained from the
human database to generate a Log2 ratio of heavy to light monoisotopic peak intensities
for each peptide ion precursor. Means of the Log2 heavy to light ratios were analyzed
using the JMP statistical program and all pairs Student t-tests.
Background searches of PKA binding partners
Two types of lists were generated: one in which all peptides found in the control
(pcDNA3.1 empty vector cotransfected with either Fyn WT or KD) were removed from
PKA transfected lanes. A second list was generated in which binding partners were
removed that were less than a five to one ratio of identified peptides in PKA transfected
lanes compared to the control. Once the lists were generated, protein functions were
assigned by searching gene symbols in both Phosphosite through Cell Signaling
Technology (http://www.phosphosite.org) as well as UniProt (http://www.uniprot.org).
In order to determine whether these proteins were novel PKA or Fyn binding partners, a
combination of searches on The Biogrid (http://thebiogrid.org) and Pubmed were
performed. Proteins were determined to be substrates of both PKA and/or Fyn by using
the “substrates of” tool on Phosphosite.
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Binding partner validation: Western Blots
HEK 293 cells were transfected with using PEI with 2 µg of Fyn WT or pcDNA3.1
empty vector serum and starved for 24 hours, followed by harvesting after another 24
hours (total growth was 48 hours). Cells were lysed in 25 mM Tris pH 7.2, 1% Igepal,
137 mM NaCl, 25 mM NaF, 1 mM sodium pyrophosphate, 1 mM DTT (dithiothreitol),
HALT protein inhibitor cocktail, 1 mM sodium othrovanadate, and 10% glycerol, and
lysates were immunoprecipitated with 2 µg α-GFP (Life Technologies, Cat# A11122).
Immunoprecipiatates and 2 mg of whole cell extract were subjected to immunoblot
analysis using α-PKACα (Santa Cruz Cat# sc-903), or with the following antibodies: αAKAP9 (Bethyl, Cat# A301-662A), α-CDK5RAP2 (Bethyl, Cat# A300-554A, αPDE4DIP (Thermo Scientific, Cat# PA5-30324), α-LARP4 (Bethyl, Cat# A303-900A), α
-Fyn (Santa Cruz, Cat# sc-16) and α-Tubulin (Cell Signaling, Cat# 3873).
3.5. Results
A summary depicting inter-regulatory events proximal to RTKs, Fyn and PKA is
shown as a model in Figure 15A. RTKs can phosphorylate SFKs (including Fyn) and
PKA (on tyrosine 330). PKA can phosphorylate Fyn on serine 21 and increase Fyn’s
kinase activity. Fyn can phosphorylate PKA on tyrosine 69, resulting in increases in
PKA’s activity. PKA and Fyn are also able to co-immunoprecipitate (Figure 15B).
Transfection with either Fyn WT or KD both resulted in increases in α-phospho-PKA
substrate compared to the empty vector control (Figure 15C). Furthermore, PKA and
Fyn appear to have similar immunofluorescence profiles, and quantitative analysis
reveals colocalization (Figure 16A, B). From these data, it appears as though Fyn and
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PKA are interacting with one another. We hypothesized there is potential for a signaling
cascade downstream of this interaction, and that Fyn could lead to differences in PKA
binding partners.
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Figure 15: Fyn and PKA phosphorylate one another, and regulate each other’s activity. A: Model of
proximal crosstalk between RTKs, PKA and SFKs (Fyn). PKA is able to phosphorylate S21 on the
N-terminus of Fyn and increase Fyn’s kinase activity. The catalytic subunit of PKA is
phosphorylated on Y330 downstream of receptor tyrosine kinases (RTKs). PKA is also
phosphorylated on Y69 by the SFK Fyn, which increases PKA’s kinase activity. RTKs can also lead
to SFK activation. B: PKA and Fyn co-immunoprecipitate. Cells were transfected with either WT or
KD constructs. Endogenous catalytic subunit of PKA was immunoprecipitated, followed by western
blotting for α-Fyn or α-PKA-c. Credit: Sam Barritt and Dr. Paula Deming. C: Fyn increases PKA’s
activity. Cells were transfected with pcDNA3.1 empty vector, Fyn WT, or Fyn KD constructs and
blotted for α-phospho-PKA substrate (α-RRXpS). As a control, cells were stimulated with 30 µM
forskolin to promote increases in α-phospho-PKA substrate reactivity, indicative of PKA’s activity.
Credit: Dr. Paula Deming.
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Figure 16 B: Box and whiskers plot of Spearman’s rank correlation values comparing cells
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In order to study differences in PKA binding partners in the presence of Fyn, we
employed quantitative mass spectrometry. Stable Isotope Labeling of Amino Acids in
Cell Culture (SILAC) allows for differential labeling of cells to compare two different
treatment conditions. This enabled us to look at the effect that Fyn was having on the
ability of proteins to interact with PKA-c. PKA binding partners identified from this
study may provide insight to novel signaling pathways for future research. A model of
the SILAC experimental approach used in this study is highlighted in Figure 17.
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Two experiments were performed to investigate whether Fyn can regulate PKA binding
interactions. The first experiment aimed to identify Fyn-enhanced PKA binding
partners. Figure 18A depicts the workflow of this experiment, which compared the
profile of proteins interacting with PKA-c-YFP in the presence or absence of Fyn WT. A
total of 41 PKA binding partners were identified (Figure 18B), including 40 that showed
Fyn-enhanced binding to PKA, and one novel PKA binding partner that was Fyn
independent. To account for differences in the amount of PKA-c-YFP
immunoprecipitated, the mean heavy-to-light (H/L) ratio was compared to YFP and
plotted based on their fold change (Figure 18C). Using the literature and PhosphoSite,
we categorized these proteins as known substrates or known binding partners of either
PKA or Fyn. Although several of the proteins we identified in our screen were known
interactions, many were found to be novel PKA binding proteins (Figure 18D). The total
list of proteins from this experiment was further characterized based on their function
within the cell (Figure 18E) based on searches using Phosphosite and UniProt, some of
which included AKAPs, microtubule/cytoskeletal components, and metabolism. Three
proteins were chosen for further characterization due to the fact that they all had an over
four-fold increase in binding to PKA-c-YFP in the presence of Fyn WT. These include
known PKA binding partners CDK5RAP2, AKAP9/450/Yoatio, and Phosphodiesterase 4
interacting protein (PDE4DIP). LARP4 was also chosen for further characterization as it
is a protein with little known function and we identified it as a novel PKA-binding
partner although it did not show a Fyn-dependent change. All four of these proteins are
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highlighted in Figure 18C. The respective light and heavy spectra for each protein is
displayed in Figure 19.
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Figure 19: SILAC mass spectra for four chosen PKA binding partners comparing conditions with
Fyn WT versus no Fyn. A: Representative light and heavy mass spectra for AKAP9. Mean and
standard deviation included. B: Representative light and heavy mass spectra for PDE4DIP. Mean
and standard deviation included. C: Representative light and heavy mass spectra for CDK5RAP2.
Mean and standard deviation are included. D: Statistics for the four proteins selected for further
investigation. E: Representative light and heavy mass spectra for LARP4. Mean and standard
deviation are included. F: Representative light and heavy mass spectra for YFP. Binding partners
were compared to YFP peptides. Mean and standard deviation are included.
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In the second SILAC experiment, we aimed to identify PKA binding partners that
were dependent on Fyn’s enzymatic activity by comparing cotransfection of PKA with
either Fyn WT or KD DNA. Workflow of this experiment is first laid out in Figure 20A.
Fewer proteins were found in this experiment (23), with a majority representing Fynactivity reduced binding partners (Figure 20B). Fyn activity-reduced PKA binding
partners heavy to light (H/L) ratios were normalized to YFP and graphed (Figure 20C).
This accounted for the difference in total PKA-c-YFP between the light and heavy
treatment conditions. As for the first experiment these proteins were classified as novel,
or known substrates and/or binding partners of Fyn or PKA (Figure 20D). Proteins were
grouped based on functional classification (Figure 20E). The four proteins previously
described are highlighted. Representative spectra for AKAP9, PDE4DIP, CDK5RAP2,
and LARP4 are displayed in Figure 21.
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Figure 21: SILAC mass spectra for four chosen PKA binding partners comparing conditions with
Fyn WT versus KD. A: Representative light and heavy mass spectra for AKAP9. Mean and
standard deviation included. B: Representative light and heavy mass spectra for PDE4DIP. Mean
and standard deviation included. C: Representative light and heavy mass spectra for CDK5RAP2.
Mean and standard deviation included. D: Representative light and heavy mass spectra for YFP.
Binding partners were compared to YFP peptides. Mean and standard deviation are included. E:
Statistics for the four proteins selected for further investigation.
F: Representative light and heavy mass spectra for LARP4. Mean and standard deviation are
included.
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Between the two experiments, 12 proteins were found in both (Figure 22), including the
four proteins that were chosen for further characterization.

Total#PKA#Binding#Partners
WT#vs#Vector

29

WT#vs#KD

12

11

Figure 22: Total numbers of PKA binding partners found in the two mass spectrometry experiments.
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In order to validate binding partners identified by mass spectrometry, HEK 293
cells were co-transfected with PKA-c-YFP and either empty vector or active Fyn WT.
PKA-c-YFP complexes were captured with immunoprecipitation and subjected to SDS
PAGE immunoblot analysis for endogenous AKAP9, PDE4DIP, CDK5RAP2, and
LARP4 (Figure 23). All four of these proteins were biochemically validated to bind to
PKA-c. Moreover, AKAP9, PDE4DIP, and CDK5RAP2 showed greater binding to PKA
in the presence of Fyn.
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Figure 23: Validation of Fyn-enhanced PKA binding partners. PKA was immunoprecpitated and the
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Barritt and Dr. Paula Deming
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3.6. Discussion
Through the use of biochemical and mass spectrometry-based approaches, we
have identified several novel PKA binding partners. Some of the proteins identified are
known PKA binding partners, but have increased binding to PKA in the presence of Fyn.
We also aimed to identify PKA binding partners which were dependent on Fyn’s
enzymatic activity. Since we have shown that Fyn can phosphorylate PKA on Y69, we
originally thought that if Fyn possessed enzymatic activity, tyrosine phosphorylation by
Fyn of either PKA or other proteins could allow for new binding interactions with PKA.
We were therefore surprised to find proteins with higher levels of induced binding to
PKA in the presence of Fyn KD compared to Fyn WT (Figure 19C). It’s also interesting
to note that more Fyn KD co-immunoprecipitated with the endogenous catalytic subunit
of PKA compared to Fyn WT (Figure 14B). Furthermore, higher levels of α-phosphoPKA substrate were observed when Fyn KD was transfected compared to Fyn WT.
These data, together with the mass spectrometry results suggests that Fyn could be acting
as an intermediate or a scaffold to create certain binding protein interactions with PKA,
but that Fyn’s activity acts to negatively regulate the binding to some degree.
Three of the proteins selected for further characterization are known AKAPs of
PKA as they have been shown to bind to RII subunits of PKA and allow for their
localization to specific areas of the cell. All of these proteins displayed a four-fold
increase in binding to PKA-c-YFP when Fyn was expressed as compared to when it was
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not. These same proteins were also found in the second SILAC experiment which
compared cotransfection of PKA with either Fyn WT or KD. Interestingly, published
literature points to various interactions between these three proteins. PDE4DIP, also
known as myomegalin, (Uys et al., 2011) has been found localized to the Golgi and
centrosome (Verde et al., 2001). Myomegalin and AKAP9 (also called AKAP450 and
Yoatio) have been shown to co-localize through immunofluorescence (Roubin et al.,
2013). When myomegalin was depleted using siRNA, AKAP9 could not localize to the
Golgi, suggesting that myomegalin may be controlling AKAP9’s localization (Roubin et
al., 2013). AKAP9 and PKA can also colocalize at the centrosome, as shown through
immunofluorescence microscopy (Terrin et al., 2012). Centrosomal proteins are
important not only or proliferation, but migration of neurons (Kumar et al., 2013).
CDK5RAP2 (also known as CEP215, or centrosomal protein of 215 kDa), is part of a
family of proteins that includes 32 members which are important in normal progression
of the cell cycle through the generation of mitotic spindle poles (Kumar et al., 2013).
CDK5RAP2 is able to be targeted to the Golgi and centrosome through its C-terminus.
This protein helps keep centrioles together before the centrosome separates in the G2/M
phase (Kumar et al., 2013). The CNN1 domain of CDK5RAP2 aids in the recruitment
of AKAP9 to the centrosome, which allows for proper anchorage of proteins within the
mitotic spindle. Therefore, AKAP9 has not only been shown to interact with
myomegalin, but also with CDK5RAP2. Furthermore, all three of these proteins have
been found in both the Golgi and centrosome. Src has been shown to be associated with
the centrosome through nucleation necessary for microtubule regrowth (in human
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fibroblasts and CHO-K1 cells(ovarian Chinese hamster)). Src siRNA, as well as the SFK
inhibitor SU6656 showed a marked decrease in microtubule regrowth (Colello et al.,
2010). What is strikingly apparent from studies of Src, PKA, AKAP9, PDE4DIP, and
CDK5RAP2 is their localization and function in the cell involving microtubule dynamics,
suggesting a potential complex formation of these proteins in order for this process to
occur.
Although LARP4 binding to PKA-c was not shown to be statistically different in
the presence of Fyn, it is a novel PKA binding partner. Furthermore, very few papers
have been published that describe this protein. LARP4 was identified in an RNAi screen
that aimed to identify gene products which regulated cell migration (Bai et al., 2011). An
increase of cell migration was seen with LARP4 RNAi in PC3 immortalized prostate
cancer cells, but migration was not statistically significant from the siRNA control (Bai et
al., 2011). LARP4 has also been characterized as an RNA binding protein through its
association with poly(A) RNA, as well as poly(A) binding protein (PABP) (Yang et al.,
2011). The low number of previous studies, along with LARP4’s potential connection
with cell migration, make it an interesting candidate for studying novel relationships with
PKA.
The data presented in this chapter suggest that Fyn could be stabilizing a complex
of proteins with PKA (Figure 24). AKAP9, CDK5RAP2, and PDE4DIP can bind to the
regulatory subunits of PKA, which could allow for PKA to be subjected to a specific pool
of cAMP, initiating activation and phosphorylation of specific substrates, resulting in
certain functional readouts. It has been confirmed through in vitro kinase assays and
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mass spectrometry that Fyn phosphorylates PKA on Y69, implying that the enzymatically
active form (Fyn WT) can phosphorylate PKA directly. Perhaps phosphorylation at this
residue in turn may cause Fyn WT to bind less well (either directly or indirectly) to PKA
(Figure 24A). Other groups have shown that phosphorylation events can lead to
disruptions in protein docking between two kinases. An example is the MAPK (ERK),
which binds to RSK at its C-terminus. After RSK becomes active it autophosphorylates
at the MAPK binding site, reducing the affinity of MAPK for RSK (Roux et al., 2003).
Perhaps Fyn stabilizes certain protein complexes for PKA, but once PKA is
phosphorylated this complex is no longer stable. Lack of complex stability would
decrease the ability of PKA to phosphorylate these particular substrates, resulting in a
decrease of the total amount of α-phospho-PKA substrate. Fyn KD, however, can not
phosphorylate PKA on Y69, so it is able to bind to PKA (either directly or indirectly),
stabilizing a complex of a particular set of AKAPs which can bind to the regulatory
subunits of the protein (Figure 24B). This might occur under basal activity levels (in the
absence of growth factors). Upon growth factor stimulation, Fyn activity could increase,
and the kinase could subsequently autophosphorylate its SH2 domain on Y185, Y213,
and Y214, leading to dissociation of the complexed proteins that subsequently bound to
the regulatory subunits of PKA. AKAP proteins that were complexed by Fyn could then
transport the PKA holoenzyme to specific areas of the cell to interact with discrete pools
of cAMP. Phosphorylation of PKA on Y69 could reduce the binding of particular
proteins complexed by Fyn as a means to protect the pathway from becoming
constitutively active. Experiments to test this idea are outlined in Chapter 4 of this
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dissertation. Furthermore, research to uncover changes specific PKA substrates in
response to Fyn is currently underway.
PKA is involved in many different cellular processes, including cell growth and
migration. Perhaps the presence of Fyn could allow for PKA to interact with proteins
important for cytoskeletal dynamics, allowing for increases in cell migration. This seems
plausible based on the known functions of the four proteins chosen for further
characterization from the SILAC mass spectrometry experiment: AKAP9, PDE4DIP,
CDK5RAP2 and LARP4. A scratch wound assay could potentially provide differences
in cell migration based on overexpression of these four proteins. Rates of migration
could be compared with cells solely overexpressing PKA, versus those overexpressing
PKA with Fyn, or PKA, Fyn, and one of the four other proteins chosen through our mass
spectrometry experiments. Mutants of Fyn, including the 3D mutant described in
Chapter 2 of this dissertation could also be overexpressed to determine if migration rates
differed compared to Fyn WT. siRNA of the proteins described above could also be used
to determine whether specific gene knockdown affects migration in a scratch wound
assay. Perhaps knockdown of this complex (including Fyn, PKA, and the AKAPs
identified in the SILAC experiment) could allow for differences in cell migration speed.
These ideas could be tested with future experiments.
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Figure 24: Proposed model of interaction between Fyn WT versus Fyn KD and PKA.
Phosphotyrosines of proteins X, Y, and Z (i.e., AKAPs) can bind to the SH2 domain of Fyn
WT. Fyn can then complex these proteins with PKA and bind to proline-rich regions within
the regulatory subunits of PKA. Active Fyn can phosphorylate PKA on Y69.
Phosphorylation of this protein decreases protein docking of Fyn. Distinct pools of cAMP
could then interact with PKA through binding to its regulatory subunits. Subsequent
dissociation of PKA’s catalytic subunits could then occur. B: Proposed model of interaction
between Fyn KD and PKA. Phosphotyrosines of proteins X, Y, and Z (i.e., AKAPs) can bind
to the SH2 domain of Fyn KD. Fyn can subsequently complex these proteins to PKA and
bind to the proline-rich regions located on the regulatory subunits of PKA. Since Fyn can
not phosphorylate PKA on Y69, the protein remains bound to Fyn, allowing for AKAPs
bound to Fyn’s SH2 domain to interact with the regulatory subunits of PKA. Fyn could
subsequently autophosphorylate its own SH2 domain on Y185, Y213, and Y214 to decrease
binding to proteins X, Y, and Z, allowing for these proteins to transport the holoenzyme to
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CHAPTER 4: SUMMARY OF FINDINGS AND FUTURE DIRECTIONS
4.1. Summary of findings and future directions for Chapter 2
Four novel tyrosine phosphorylation sites on the Src family kinase Fyn were
characterized through biochemical and mass spectrometry techniques. These four
residues were found to be autophosphorylation sites. Mimicking phosphorylation of
Y185, Y213, and Y214 increased kinase activity, while decreasing protein binding to
the SH2 domain. Mimicking phosphorylation on Y440 decreased kinase activity.
Taken together, the four residues that were investigated, Y185, Y213, Y214, and Y440
are conserved in many of the other Src Family Kinase members, which may also be
important for regulation of activity and substrate binding of these proteins.
It has been shown both in previous studies as well as data provided in this
dissertation that SFKs have many regulatory mechanisms in place. This idea seems
obvious; many proteins need regulation in order to not be in a constant active state.
Disturbances in regulation resulting in continuous signaling have been widely reported
to lead to diseased states such as cancer. The two canonical phosphorylation sites
Y531 and Y420 on Fyn are clear examples of activating and inhibitory phosphorylation
events, and have previously been widely-studied and characterized. The findings from
this dissertation show that the three sites of tyrosine phosphorylation in the SH2
domain seem to provide another mechanism of regulation for the kinase. One possible
reason for this finding could be that there a shift toward a reduced proportion of SH2
binding partners/substrates of Fyn. For example, upon activation of RTKs several
proteins in the cell become tyrosine phosphorylated which can recruit Fyn (and likely
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other SFKs). Fyn binding to these proteins will relieve autoinhibition and activate Fyn.
After a certain amount of time, active Fyn would begin to phosphorylate its SH2
domain and leave a higher proportion bound to the other proteins via its SH3 domain.
In order to study this idea, Fyn SH2 single, as well as triple aspartic acid mutants (3D)
could be transiently cotransfected into HEK 293 cells with a known Fyn SH3 binding
partner, followed by coimmunoprecipitations. Wildtype Fyn would also be
cotransfected as a control. Following immunoprecipitation and blotting for known Fyn
SH3-binding partners (e.g. p85 PI3K) as well as known Fyn-SH2 binding partners (e.g.
FAK) one might observe a change in the proportion of proteins bound to the SH2
domain compared to the SH3 domain when Y185, Y213, or Y214 are phosphorylated.
A simultaneous drop in α-phosphotyrosine signal might be observed on Fyn’s SH2
binding partners with either no change or an increase in phosphotyrosine signal on
Fyn’s SH3 binding partners. The proportion of these binding partners or specific sites
of tyrosine phosphorylation could also be quantified using a SILAC approach
comparing the WT Fyn and the Fyn 3D in immunoprecipitation experiments. For
example, cells grown in light media would be cotransfected with Fyn 3D and a known
Fyn SH3 binding partner. Cells grown in heavy-labeled media would be transfected
with Fyn WT and a known Fyn SH3 binding partner. Both conditions would be lysed
and immunoprecipitated for Fyn, then combined and run on an SDS-PAGE gel for
mass spectrometry analysis. The relative abundance of the known Fyn SH3 binding
partner, as well as phosphotyrosine-containing proteins bound to the SH2 domain,
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could be compared between the two treatment conditions and differences could be
quantified with mass spectrometry.
It appears that in addition to the three characterized tyrosine phosphorylation
sites, there is at least one, if not more than one additional tyrosine in the SH2 domain is
phosphorylated. Creation of additional phenylalanine mutants could be employed,
followed by determining the phosphotyrosine signal after an in vitro kinase assay with
these mutants to identify the additional site(s) of tyrosine phosphorylation. “4F”
mutants could be initially created in which Y185, Y213, and Y214 plus one of the other
three tyrosine residues in the SH2 domain all mutated to phenylalanines. If residual
phosphorylation was still observed in each of the three 4F mutants (each one of which
mutated one of the three other tyrosines in the SH2 domain), then 5F or 6F mutants
could also be created and analyzed for phosphotyrosine signal after in vitro kinase
assays.
Previous work has shown that c-Src mutants exhibit transforming ability in cells,
causing foci formation on soft agar (Piwnica-Worms et al., 1987). NIH 3T3 (mouse
embryonic fibroblast) cells transfected with the Src Y527F mutant showed foci formation
that was 100 to 500 fold higher compared to WT (Cartwright et al., 1987). It would be
interesting to determine if the Fyn 3D mutant showed foci formation in the same assay.
Based on the data outlined in Chapter 2, it is hypothesized that the transforming ability of
the 3D mutant would be greater than that of WT, but not as great as the Y531F mutant.
This could be because of the decrease in protein binding to the SH2 domain. Perhaps the
kinase needs interactions with other proteins through binding to its SH2 domain in order
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to effectuate signals needed for transformation. Fyn 3D mutant cells could also be
injected in nude mice to observe tumor formation. Speed of tumor formation would be
compared to Fyn WT, as well as the Y531F mutant. Invasion assays could also be
performed comparing WT and mutant transfected cells in a Boyden chamber with filter
separation to monitor the degree of invasion.
Another hypothesis is that the regulation of these various phosphorylation events
could be happening at particular times after growth factor stimulation. Perhaps
phosphorylation of one or several of the tyrosine residues occurs in a stepwise fashion in
order to increase, and subsequently decrease Fyn’s kinase activity necessary for
regulation. Cells expressing endogenous Fyn would be stimulated with PDGF (in a time
course) and western blotted for phospho-specific antibodies (which could be generated
for pY440, pY185, etc). The amount of tyrosine phosphorylation on each of these
residues could also be quantified by comparison to a synthetic (AQUA) peptides to
determine how much tyrosine phosphorylation changed on specific residues throughout
PDGF stimulation. It is hypothesized that Y420, Y185, Y213, Y214, and Y440 would be
phosphorylated after different lengths of time once stimulated with PDGF. We predict
that Y420 would be phosphorylated first, followed by phosphorylation of Y185, Y213,
and Y214. Phosphorylation of Y440 is predicted to occur long after PDGF stimulation
based on the data we provide in Chapter 2, suggesting that phosphorylation of this
tyrosine residue allows for decreases in kinase activity which aids in regulation.
Although we have shown that Y185, Y213, Y214, and Y440 are intermolecular
autophosphorylation sites, there is also a possibility that these tyrosine residues can be
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phosphorylated by other kinases in the cell. In order to determine whether or not this is
true, tyrosine kinase family inhibitors could be initially used on whole cell extracts
expressing endogenous Fyn, followed by western blotting with phospho-specific
antibodies (for pY185, pY213, etc) to in order to determine changes in phosphorylation
state. This could be narrowed down further with overexpression of specific kinases,
as well as in vitro kinase assays with molecules of Fyn and the candidate kinase.
4.2. Summary of findings and future directions for Chapter 3
Although there are several lines of evidence which indicate interactions between
PKA and Fyn, the binding mechanism between these two proteins is unclear. Given that
wildtype Fyn binds less well to PKA than the kinase-dead form, Fyn’s enzymatic activity
affects its interaction with PKA. Exactly what part of each molecule is involved in the
interaction hasn’t been identified. One way by which Fyn could interact with PKA is
through Fyn’s SH3 domain. Based on the proline-rich regions found in three of the four
PKA regulatory subunits, it is hypothesized that Fyn can bind to the regulatory subunit of
PKA through its SH3 domain (Figure 25). Likely candidates for this interaction would
be regulatory type I alpha, type I beta, or type II alpha (Figure 25 A-C). PKA regulatory
subunit type II beta does not contain proline-rich regions.
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A
PKARI&alpha&
MESGSTAASEEARSLRECELYVQKHNIQALLKDSIVQLCTARPERPMAFLREYFERLEKE4
EAKQIQNLQKAGTRTDSREDEISPPPPNPVVKGRRRRGAISAEVYTEEDAASYVRKVIPK4
DYKTMAALAKAIEKNVLFSHLDDNERSDIFDAMFSVSFIAGETVIQQGDEGDNFYVIDQG4
ETDVYVNNEWATSVGEGGSFGELALIYGTPRAATVKAKTNVKLWGIDRDSYRRILMGSTL4
RKRKMYEEFLSKVSILESLDKWERLTVADALEPVQFEDGQKIVVQGEPGDEFFIILEGSA4
AVLQRRSENEEFVEVGRLGPSDYFGEIALLMNRPRAATVVARGPLKCVKLDRPRFERVLG4
PCSDILKRNIQQYNSFVSLSV4
4

B

PKARI&beta&
MASPPACPSEEDESLKGCELYVQLHGIQQVLKDCIVHLCISKPERPMKFLREHFEKLEKE2
ENRQILARQKSNSQSDSHDEEVSPTPPNPVVKARRRRGGVSAEVYTEEDAVSYVRKVIPK2
DYKTMTALAKAISKNVLFAHLDDNERSDIFDAMFPVTHIAGETVIQQGNEGDNFYVVDQG2
EVDVYVNGEWVTNISEGGSFGELALIYGTPRAATVKAKTDLKLWGIDRDSYRRILMGSTL2
RKRKMYEEFLSKVSILESLEKWERLTVADALEPVQFEDGEKIVVQGEPGDDFYIITEGTA2
SVLQRRSPNEEYVEVGRLGPSDYFGEIALLLNRPRAATVVARGPLKCVKLDRPRFERVLG2
PCSEILKRNIQRYNSFISLTV2
2

C

D

PKARII&alpha&
MSHIQIPPGLTELLQGYTVEVLRQQPPDLVEFAVEYFTRLREARAPASVLPAATPRQSLG1
HPPPEPGPDRVADAKGDSESEEDEDLEVPVPSRFNRRVSVCAETYNPDEEEEDTDPRVIH1
PKTDEQRCRLQEACKDILLFKNLDQEQLSQVLDAMFERIVKADEHVIDQGDDGDNFYVIE1
RGTYDILVTKDNQTRSVGQYDNRGSFGELALMYNTPRAATIVATSEGSLWGLDRVTFRRI1
IVKNNAKKRKMFESFIESVPLLKSLEVSERMKIVDVIGEKIYKDGERIITQGEKADSFYI1
IESGEVSILIRSRTKSNKDGGNQEVEIARCHKGQYFGELALVTNKPRAASAYAVGDVKCL1
VMDVQAFERLLGPCMDIMKRNISHYEEQLVKMFGSSVDLGNLGQ1
1
PKARII&beta&
MSIEIPAGLTELLQGFTVEVLRHQPADLLEFALQHFTRLQQENERKGTARFGHEGRTWGD3
LGAAAGGGTPSKGVNFAEEPMQSDSEDGEEEEAAPADAGAFNAPVINRFTRRASVCAEAY3
NPDEEEDDAESRIIHPKTDDQRNRLQEACKDILLFKNLDPEQMSQVLDAMFEKLVKDGEH3
VIDQGDDGDNFYVIDRGTFDIYVKCDGVGRCVGNYDNRGSFGELALMYNTPRAATITATS3
PGALWGLDRVTFRRIIVKNNAKKRKMYESFIESLPFLKSLEFSERLKVVDVIGTKVYNDG3
EQIIAQGDSADSFFIVESGEVKITMKRKGKSEVEENGAVEIARCSRGQYFGELALVTNKP3
RAASAHAIGTVKCLAMDVQAFERLLGPCMEIMKRNIATYEEQLVALFGTNMDIVEPTA3
3

Figure 25: PKA regulatory subunits contain proline-rich regions. A: Amino acid
sequence of human PKA regulatory I alpha, with a proline-rich region highlighted in
yellow. B: Amino acid sequence of human PKA regulatory I beta, with proline-rich
regions highlighted in yellow. C: Amino acid sequence of human PKA regulatory II
alpha, with a proline-rich region highlighted in yellow. D: Amino acid sequence of
human PKA regulatory II beta, which does not contain any proline-rich regions.
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The data presented in Chapter 3 of this dissertation show that kinase-dead Fyn
leads to higher levels of Fyn-dependent PKA binding partners compared to wildtype
Fyn. This might be due to the ability of Fyn to phosphorylate PKA-c, perhaps on Y69.
One experiment to test this hypothesis would be to compare the effect of Fyndependent binding partners of PKA-c WT versus the PKA-c Y69F mutant, which is not
able to be phosphorylated on that particular residue by Fyn. Additionally, it is
predicted that cotransfection of PKA-c Y69F with Fyn WT would yield similar αphospho-PKA substrate levels in whole cell extracts as PKA-c WT and Fyn KD
cotransfections, as Fyn WT cotransfected with PKA-c showed slightly lower levels of
α-phospho-PKA substrate in the whole cell extracts (Figure 15C). In order to quantify
these differences, SILAC mass spectrometry could be employed in order to compare
these different treatment conditions.
The current literature regarding the PKA binding partners that we chose for
further investigation from the SILAC mass spectrometry experiments (in Chapter 3)
implicates these binding partners in cell division and migration. Perhaps Fyn can
complex these proteins to PKA for this signaling to occur. However, after a certain
amount of time the complexes need to disassemble so that there is not an overactive
signal. In order to accomplish this, enzymatically active Fyn could phosphorylate PKA
on Y69 to reduce its own binding, thereby preventing PKA from interacting with the
complexed proteins and the signal can no longer be propagated. Functional readout
assays such as a cell migration scratch assay could be done in order to study this
concept. Initially, cells would be overexpressing PKA-c-YFP and Fyn WT or KD, and
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a scratch wound assay could be performed. Migration rates of YFP-positive cells
would be compared between Fyn WT and KD conditions, with the prediction that Fyn
WT overexpressed with PKA would result in faster migration rates. This might be
because migration is dependent on the dynamics found in reversible protein-protein
interactions. Perhaps Fyn’s phosphorylation of PKA-c on Y69 aids in this dynamic
interaction that could result in cytoskeletal reorganization and increases in migration
efficiency. In diseased states such as cancer, there could be an increase in SFK activity.
This might lead to overactive wildtype Fyn which could phosphorylate more molecules
of PKA-c on Y69, allowing for increases in cell migration. PKA and Fyn single
transfection migration rates would also need to be measured as a control. PKA-c Y69F
mutants would also be overexpressed to determine if a mutation in Y69 results in
differences in migration ability, predicting that this mutant would not migrate as well.
After growth factor stimulation, Fyn might complex certain proteins (like
AKAPs) to PKA which can bind to the regulatory subunits of PKA and bring the kinase
to particular pools of cAMP for activation. These complexed proteins seem to be
important in microtubule dynamics, which has implications in processes like cell
migration. Application of Src-1 (a SFK kinase activity inhibitor) is predicted to
increase the amount of proteins complexed with PKA under endogenous levels. It is
hypothesized that this would occur because endogenous Fyn would still be present, but
the Src-1 inhibitor would affect Fyn’s kinase activity. Therefore, Fyn would stay
complexed with PKA. If Fyn were knocked down, it is predicted that the complexing
of particular PKA binding partners would decrease (like the ones identified in the
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SILAC experiments). This would result in decreases in PKA’s ability to phosphorylate
these particular proteins, possibly decreasing certain protein-protein interactions
important for cytoskeletal dynamics and ultimately cell migration.
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APPENDIX: SUPPLEMENTARY IMMUNOFLUORESCENCE PANELS
A.1.1. Remarks about immunofluorescence data and future directions
Also mentioned in Chapter 3 (Figure 16), PKA-c-YFP and Fyn WT colocalize
with statistical significance as shown with a Spearman’s rank correlation value and
mean Costes P value (Figure 16B, Appendix Figure 2). A full representation of all 30
cells that were used for colocalization statistical analysis are found in Appendix Figure
4. PKA-c-YFP and Fyn KD (Appendix Figure 6) were also analyzed for colocalization
using the Spearman’s rank correlation value and mean Costes P value (Appendix
Figure 2). The mean Costes P value is very near statistical significance (0.93, where a
p value of 0.95 is considered statistically significant) when comparing PKA-c-YFP to
Fyn KD localization within the cell (Appendix Figure 2). However, the Spearman’s
rank correlation value of these data compared to analysis of the red or green channels
with DAPI is still strikingly different.
Immunofluorescence colocalization studies were also done to compare PKA and
various Fyn mutants, with the idea that mutations on Fyn could potentially lead to
changes in either PKA’s localization or colocalization differences between PKA and
Fyn mutants. Although only colocalization between PKA-c-YFP and Fyn WT or Fyn
KD were represented in Chapter 3, additional experiments were performed to compare
localization between PKA-c-YFP and other Fyn mutants. These experiments were
done with the hypothesis that expression of Fyn mutants might either change PKA’s
localization within the cell, or the two proteins may no longer colocalize. As
mentioned in Chapter’s 3 and 4, one potential mechanism of interaction between PKA
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and Fyn could be binding of Fyn’s SH3 domain to proline-rich regions on the
regulatory subunits of PKA. It was hypothesized that if Fyn did not possess it’s SH3
domain, the immunofluorescence profiles between these proteins could look different.
This however, was not the case (Appendix Figure 1A, 2, and 8). PKA-c-YFP and Fyn
Delta SH3 still colocalized with statistical significance (Appendix Figure 2). Another
potential interaction of these two proteins could be through binding of Fyn’s SH2
domain to phosphotyrosines on PKA. Based on the data presented in Chapter 2 of this
dissertation, mutation of Y185, Y213, and Y214 to aspartic acids dramatically
decreased binding of the SH2 domain to phosphotyrosine-containing proteins. If an
interaction occurred between PKA and Fyn’s SH2 domain, perhaps cotransfection of
PKA with the Fyn 3D mutant would lead to differences in PKA’s localization, or
decreases in colocalization between the two proteins. Cells cotransfected with PKA-cYFP and Fyn 3D still colocalized with statistical significance (Appendix Figure 1A, 2,
and 10). The last Fyn mutant that was visualized with immunofluorescence
microscopy was Fyn Y440D, which has also been previously described in Chapter 2 of
this dissertation. Mutation of Y440 was shown to decrease Fyn’s kinase activity.
However, based on not being able to see a difference in colocalization between PKA-cYFP and Fyn WT or KD, there might not also be a difference when Fyn Y440D was
coexpressed. This appeared to be true (Appendix Figure 1A, 2, and 12).
Colocalization still occurred with statistical significance between PKA-c-YFP and Fyn
Y440D. When comparing HEK 293 cells solely transfected with Fyn WT or mutant
constructs, the overall fluorescence localization profile did not look widely different
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(Appendix Figure 1B, 5, 7, 9, 11, and 13). This suggests that mutations in three
different domains of Fyn does not alter the protein’s localization within the cell.
Based on these data, it appears as though specific mutations within the kinase,
SH2 and SH3 domains of Fyn do not alter the protein’s localization within the cell, as
well as its ability to colocalize with PKA. There are limitations of
immunofluorescence, however, which make it difficult to draw conclusions about
specific interactions between Fyn and PKA. Meaning, although PKA and various Fyn
mutants still colocalize, this does not provide information about the biochemical
interactions that are occurring between these two proteins. If, perhaps, Fyn interacts
with PKA through binding of its SH3 domain, a Fyn Delta SH3 mutant may still
localize to the same regions of the cell, but not necessarily still be able to bind to PKA.
Further analysis of the interactions between these proteins would need to be worked out
biochemically.
Appearance of more PKA-c-YFP in cells also expressing Fyn
Based on the well-established literature in which PKA is localized to particular
regions of the cell by AKAP proteins and the documented interactions between Fyn and
PKA, it was thought that perhaps Fyn could cause a change in PKA’s localization as
well. Initially, it seemed as though the immunofluorescence profile for PKA-c-YFP
was different between sole transfection compared to cells that also expressed Fyn
(Appendix Figure 1A, 3, and 4). When a titer of transfected PKA-c-YFP alone was
analyzed with immunofluorescence and compared, it appeared as though there was
more PKA present in cells that were also expressing Fyn (versus cells transfected with
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the same amount of PKA-c-YFP alone) (data not shown). One question that arose is
whether Fyn could be altering (either directly or indirectly) the amount of PKA that is
translated in the cell. One way to quantify if this is occurring is through fluorescenceactivated cell sorting (FACS). The fluorescence of cells transfected with PKA-c-YFP
alone or with Fyn (WT or mutant constructs) could be individually sorted and
quantified based on signal intensity, which could be useful for determining if the
amount of translation differed with cells overexpressing Fyn. In the
immunofluorescence experiments, a primary Fyn antibody and red Alexafluor
secondary was used to detect overexpressed Fyn. Using this method, however, a Fyn
construct with a mcherry (red) tag would need to be used and initially visualized with
immunofluorescence to make sure that the tag is not changing the distribution of Fyn in
the cell (in comparison to previous experiments which used a fluorescent secondary
antibody). If there was a worry about differences in transfection amounts between
PKA-c-YFP alone versus PKA-c-YFP cotransfected with Fyn, cells could be compared
within the PKA-c-YFP and Fyn cotransfection group. Based on what has been
observed with immunofluorescence in the group that was cotransfected with both PKAc-YFP and Fyn, there is a percentage of cells that express PKA alone (i.e. no Fyn). An
example of this is represented in Appendix Figure 4 (fifth panel in if starting from the
top left). Within this group, cells could be sorted using FACS analysis and cells which
only possess a green signal versus those that possess both a green and red signal could
be quantified to determine amount of translation.
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Accounting for the large difference in the amount of DNA transfected between PKA and
Fyn
Although a great deal of experiments were done using immunofluorescence,
further work needs to be done to address some of the issues with experimental design.
Initially, HEK 293 cells were transiently transfected with a titer of DNA for both PKAc-YFP and Fyn (either Fyn WT or KD). Worrying that overexpression of too much
PKA-c-YFP would cause the protein to localize to parts of the cell in which it normally
does not, a concentration of 0.01µg PKA-c-YFP was chosen. This particular
concentration was chosen because it was the lowest concentration that could be
transfected into the cells where it could still be visible with immunofluorescence.
Initial experiments aimed to see if there was a difference in PKA’s localization based
on the presence of Fyn. A titer of both Fyn WT and Fyn KD of 2, 4, and 6 µg were
initially chosen. It was reasoned that larger concentrations of Fyn could be used to
increase levels within the cell above endogenous in order to see a potential effect.
Simple observation of PKA-c-YFP compared to PKA-c-YFP with Fyn revealed what
seemed to be differences in PKA localization. PKA-c-YFP alone appeared to have
punctate localization within the cell, whereas PKA-c-YFP contransfected with Fyn
appeared to be more diffuse. There did not seem to be a difference in PKA localization
when 2, 4, or 6 µg of Fyn WT or KD was transfected, so 2 µg was chosen to be used
for subsequent experiments.
A caveat of this experimental design is the large difference in concentration
transfected between PKA and Fyn. In order to resolve this issue, it will be necessary to
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repeat the experiments using identical concentrations of Fyn and PKA. In regards to
uncovering whether PKA and Fyn colocalize, it might also be useful to first look at
localization using the same concentrations (2 µg of each) that were used in the original
SILAC experiment. These experiments will be repeated under these conditions and
quantified with ImageJ Coloc2 software to determine Spearman’s rank correlation
values and Costes P values. However, the Spearman’s rank correlation statistical
analysis that was chosen takes into account differences in signal intensity between
channels because of the way that the values are nominally ranked. For this reason, the
Spearman’s statistical analysis was chosen to study colocalization of these experiments
instead of a Pearson’s statistical analysis, which can not account for differences in
signal intensity.
Proposed experiment: visualizing endogenous and/ or transfected regulatory subunits
of PKA
All of the immunofluorescence data presented in Chapter 3, as well as the
Appendix only looks at the localization of the catalytic subunit of PKA with respect to
Fyn. Based on the well-established literature involving regulatory subunit localization
with AKAPs, it would also be interesting to look at the regulatory subunit of PKA and
its localization within the cell using immunofluorescence. Endogenous, as well as
transfected fluorescently-tagged constructs could be used to address localization
questions. To look at endogenous PKA regulatory subunits, cells could either be
transected with an empty vector plasmid or with Fyn (WT or mutants). If Fyn and the
regulatory subunit of PKA appear to localize to the same area of the cell, colocalization
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can be studied using a plugin of ImageJ (FIJI) to generate Spearman’s rank correlation
values and mean Costes P values for analysis of statistical significance.

A.1.2. Materials and Methods
Plasmids
pRK5 c-Fyn (16032), pRK5 DN-Fyn (16033), and pRK5 Fyn deltaSH3 (16034) were
all purchased from Addgene (Cambridge, MA, USA). Fyn 3D and Fyn Y440D mutants
were created as described in the Materials and Methods section of Chapter 2 in this
dissertation. PKA-c-YFP was a gift from M. Zaccolo from the University of Padua (as
described in the Materials and Methods section of Chapter 3).
Transfections
HEK 293 cells grown on glass coverslips were transiently transfected using calcium
phosphate (Promega, Cat# E1200). Cells were grown for six hours in the transfection
reagents, followed by a warm PBS wash and fresh DMEM with 10% serum. The
following day, coverslips were fixed with 3.7% paraformaldehyde for 10 minutes, with
a subsequent gentle wash of PBS. Slides were then incubated with permeant containing
0.5% Triton-X-100 for 10 minutes, followed by a gentle wash with PBS. Incubation
with α-Fyn (α-Rabbit, Santa Cruz, Cat# sc-16) was performed at room temperature for
one hour in 1.5% BSA in PBS. Slides were washed five times, each for five minutes,
with PBS. Alexa 555 (α-Rabbit, CST Cat# 4413S) secondary was added for 45
minutes at 4° in 2% BSA in PBS. Cells were washed five times with PBS and mounted
with DAPI hardset (Vectashield, Cat # 14-1500).
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Confocal imaging and FIJI image analysis
Slides were imaged using a Nikon Eclipse Ti inverted microscope with a 40X objective
and 2X zoom to generate 80X images. RGB images were generated in Adobe
Photoshop. Original nd2 files generated from the confocal microscope were opened in
a plugin of ImageJ (FIJI) to perform colocalization studies. 30 cells were outlined with
the draw tool, and green and red channels were compared to each other using Coloc 2.
30 cells were selected to compare red (Fyn) and green (PKA-c-YFP) channels.
Spearman’s rank correlation values were put into GraphPad Prism to generate box and
whiskers plots with a 5-95 percentile setting. Mean Costes P values and standard
deviations were also calculated. Statistical significance is represented by a P value of
0.95 or higher. These statistical methods were chosen due to the fact that they can
account for differences in signal intensity. This was necessary for these experiments
because of the large difference in Fyn transfected in cells compared to PKA-c-YFP.
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Appendix Figure 1: Immunofluorescence profiles of PKA cotransfected with Fyn wildtype or various
Fyn mutants. A: Single representative images for PKA-c-YFP transfected alone or with various Fyn
mutants in HEK 293 cells. Channels are indicated on the left. Scale bar: 20 µm. B: Single
representative images of Fyn WT and mutants transfected in HEK 293 cells. Red: Fyn. Scale bar: 20
µm.
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Appendix Figure 2: A: Box and whiskers plot of Spearman’s rank correlation values comparing
transfected with PKA-c-YFP and Fyn wildtype or various Fyn mutants. Colocalization of 30 cells were
compared between green (PKA-c-YFP) vs. red (Fyn) channels. B: Mean Costes P values and standard
deviations comparing 30 cells transfected with PKA-c-YFP and Fyn WT or mutants. Statistically
significant values are in bold (Costes P value significance= 0.95 or greater).
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Appendix Figure 3: Immunofluorescence data representing 30 HEK 293 cells transiently transfected
with 0.01 µg of PKA-c-YFP. Green: PKA-c-YFP. Scale bar: 20 µm.
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Appendix Figure 4: Immunofluorescence data representing 30 HEK 293 cells
transiently transfected with 0.01 µg of PKA-c-YFP and 2 µg of Fyn WT. A: Green:
PKA-c-YFP. B: Red: Fyn. C: Merge. Scale bar: 20 µm.
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Appendix Figure 5: Immunofluorescence data representing 30 HEK 293 cells transiently transfected
with 2 µg of Fyn WT. Red: Fyn. Scale bar: 20 µm.
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Appendix Figure 6: Immunofluorescence data representing 30 HEK 293 cells
transiently transfected with 0.01 µg PKA-c-YFP and 2 µg of Fyn KD. A: Green:
PKA-c-YFP. B: Red: Fyn. C: Merge. Scale bar: 20 µm.
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Appendix Figure 7: Immunofluorescence data representing 30 HEK 293 cells transiently transfected
with 2 µg Fyn KD. Red: Fyn. Scale bar: 20 µm.
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Appendix Figure 8: Immunofluorescence data representing 30 HEK 293 cells transiently
transfected with 0.01 µg PKA-c-YFP and 2 µg of a Fyn mutant lacking the SH3 domain. A:
Green: PKA-c-YFP. B: Red: Fyn. C: Merge. Scale bar: 20 µm.
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Appendix Figure 9: Immunofluorescence data for 30 HEK 293 cells transiently transfected with 2 µg
of a Fyn mutant lacking the SH3 domain. Red: Fyn. Scale bar: 20 µm.
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Appendix Figure 10: Immunofluorescence data representing 30 HEK 293 cells transiently
transfected with 0.01 µg PKA-c-YFP and 2 µg of Fyn 3D (Y185, Y213, and Y214 mutated to an
aspartic acid). A: Green: PKA-c-YFP. B: Red: Fyn. C: Merge. Scale bar: 20 µm.
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Appendix Figure 11: Immunofluorescence data representing 30 HEK 293 cells transiently
transfected with 2 µg of Fyn 3D (Y185, Y213, Y214 mutated to an aspartic acid). Red: Fyn. Scale
bar: 20 µm.

143

A

20µm

B

20µm

C

20µm

Appendix Figure 12: Immunofluorescence data representing 30 HEK 293 cells transiently
transfected with 0.01 µg PKA-c-YFP and 2 µg Fyn Y440D. A: Green: PKA-c-YFP. B: Red:
Fyn. C: Merge. Scale bar: 20 µm.
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Appendix Figure 13: Immunofluorescence data representing 30 HEK 293 cells transiently transected
with 2 µg Fyn Y440D. Red: Fyn. Scale bar: 20 µm.

145

FUNDING SUPPORT
This work was supported by U.S. National Science Foundation IOS grant 1021795, the
Vermont Genetics Network through U. S. National Institutes of Health Grant
8P20GM103449 from the INBRE program of the NIGMS, and U.S. National Institutes of
Health Grants 5P20RR016435 and P20RR021905 from the COBRE program of the
NIGMS.

146

